CHEBI ONTOLOGY - ANNOTATIONS |
|
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
|
Term: | chalcogen |
|
Accession: | CHEBI:33303
|
browse the term
|
Definition: | Any p-block element belonging to the group 16 family of the periodic table. |
Synonyms: | exact_synonym: | chalcogens |
| related_synonym: | Chalkogen; Chalkogene; anfigeno; anfigenos; calcogeno; calcogenos; chalcogene; chalcogenes; group 16 elements; group VI elements |
| xref: | PMID:17084588 |
|
|
|
G |
NR1I3 |
nuclear receptor subfamily 1 group I member 3 |
increases activity multiple interactions |
EXP |
artemisinin results in increased activity of NR1I3 protein; artemisinin results in increased activity of NR1I3 protein alternative form; artemisinin results in increased activity of NR1I3 protein mutant form androstan-3-ol inhibits the reaction [artemisinin results in increased activity of NR1I3 protein mutant form]; artemisinin inhibits the reaction [androstan-3-ol results in decreased activity of NR1I3 protein alternative form]; artemisinin inhibits the reaction [Imidazoles results in decreased activity of NR1I3 protein alternative form]; Imidazoles inhibits the reaction [artemisinin results in increased activity of NR1I3 protein mutant form] |
CTD |
PMID:21778469 PMID:27732639 |
|
NCBI chr38:21,252,874...21,257,951
Ensembl chr38:21,253,089...21,258,827
|
|
|
G |
NPPA |
natriuretic peptide A |
affects abundance |
EXP |
NPPA protein affects the abundance of Epinephrine |
CTD |
PMID:2951327 |
|
NCBI chr 2:84,406,317...84,408,115
Ensembl chr 2:84,396,073...84,408,385
|
|
|
G |
ADRB1 |
adrenoceptor beta 1 |
increases activity |
EXP |
Norepinephrine results in increased activity of ADRB1 protein |
CTD |
PMID:10344530 |
|
NCBI chr28:24,908,224...24,909,684
Ensembl chr28:24,908,224...24,909,684
|
|
G |
ADRB2 |
adrenoceptor beta 2 |
multiple interactions |
EXP |
[Propranolol binds to and results in decreased activity of ADRB2 protein] which results in decreased secretion of Norepinephrine |
CTD |
PMID:2884805 |
|
NCBI chr 4:60,048,502...60,050,447
Ensembl chr 4:59,941,517...60,050,298
|
|
G |
NPPA |
natriuretic peptide A |
increases expression |
EXP |
Norepinephrine results in increased expression of NPPA protein |
CTD |
PMID:8952593 |
|
NCBI chr 2:84,406,317...84,408,115
Ensembl chr 2:84,396,073...84,408,385
|
|
G |
PIK3CG |
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma |
multiple interactions increases activity |
EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[Norepinephrine results in increased activity of PIK3CG protein] which results in increased chemical synthesis of phosphatidylinositol 3-phosphate]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased activity of PIK3CG protein]; [Norepinephrine results in increased activity of PIK3CG protein] which results in increased chemical synthesis of phosphatidylinositol 3-phosphate |
CTD |
PMID:15958164 |
|
NCBI chr18:13,576,966...13,611,748
Ensembl chr18:13,570,999...13,611,141
|
|
G |
POMC |
proopiomelanocortin |
increases response to substance |
EXP |
POMC protein results in increased susceptibility to Norepinephrine |
CTD |
PMID:6279499 |
|
NCBI chr17:19,431,396...19,438,247
Ensembl chr17:19,431,585...19,434,440
|
|
G |
PRKCZ |
protein kinase C zeta |
multiple interactions increases phosphorylation |
EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased phosphorylation of PRKCZ protein] |
CTD |
PMID:15958164 |
|
NCBI chr 5:57,012,020...57,113,346
Ensembl chr 5:57,012,070...57,112,664
|
|
G |
REN |
renin |
increases activity |
EXP |
Norepinephrine results in increased activity of REN protein |
CTD |
PMID:8952593 |
|
NCBI chr38:744,540...766,998
Ensembl chr38:744,614...755,012
|
|
|
G |
PLCG1 |
phospholipase C gamma 1 |
decreases activity multiple interactions |
EXP |
1,2-Dipalmitoylphosphatidylcholine results in decreased activity of PLCG1 protein dipalmitoylphosphatidic acid inhibits the reaction [1,2-Dipalmitoylphosphatidylcholine results in decreased activity of PLCG1 protein] |
CTD |
PMID:2001791 |
|
NCBI chr24:29,198,536...29,213,899
Ensembl chr24:29,198,556...29,214,714
|
|
|
G |
HSPA5 |
heat shock protein family A (Hsp70) member 5 |
increases expression |
EXP |
Dithiothreitol metabolite results in increased expression of HSPA5 protein |
CTD |
PMID:17416481 |
|
NCBI chr 9:57,850,870...57,855,607
Ensembl chr 9:57,850,922...57,855,257
|
|
|
G |
PLCG1 |
phospholipase C gamma 1 |
increases activity |
EXP |
1-stearoyl-2-arachidonoylphosphatidic acid results in increased activity of PLCG1 protein |
CTD |
PMID:2001791 |
|
NCBI chr24:29,198,536...29,213,899
Ensembl chr24:29,198,556...29,214,714
|
|
|
G |
HIF1A |
hypoxia inducible factor 1 subunit alpha |
increases expression |
EXP |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HIF1A protein |
CTD |
PMID:17658243 |
|
NCBI chr 8:36,614,045...36,656,692
Ensembl chr 8:36,614,045...36,656,692
|
|
|
G |
CPNE6 |
copine 6 |
increases reduction |
EXP |
DHRS4 protein results in increased reduction of 16-ketoestrone |
CTD |
PMID:17827741 |
|
NCBI chr 8:4,046,532...4,058,498
Ensembl chr 8:4,046,544...4,084,744
|
|
|
G |
ABCC2 |
ATP binding cassette subfamily C member 2 |
affects transport |
EXP |
ABCC2 protein affects the transport of Estradiol |
CTD |
PMID:15507541 |
|
NCBI chr28:12,670,885...12,740,124
Ensembl chr28:12,670,885...12,740,740
|
|
G |
ESR1 |
estrogen receptor 1 |
affects expression |
EXP |
Estradiol affects the expression of ESR1 protein |
CTD |
PMID:16483645 |
|
NCBI chr 1:42,081,952...42,368,544
Ensembl chr 1:42,081,969...42,368,544
|
|
|
G |
SLCO1B2 |
solute carrier organic anion transporter family member 1B2 |
increases transport |
EXP |
SLCO1B3 protein results in increased transport of estradiol-17 beta-glucuronide |
CTD |
PMID:20079461 |
|
NCBI chr27:26,411,008...26,496,174
Ensembl chr27:26,411,010...26,470,989
|
|
|
G |
SOD2 |
superoxide dismutase 2 |
multiple interactions |
EXP |
Dihydrotestosterone promotes the reaction [Hydrogen Peroxide results in decreased activity of SOD2 protein] |
CTD |
PMID:16682413 |
|
NCBI chr 1:48,943,472...48,955,158
Ensembl chr 1:48,836,262...48,955,706
|
|
|
G |
ABCB1 |
ATP binding cassette subfamily B member 1 |
multiple interactions |
EXP |
[Verapamil results in decreased activity of ABCB1 protein] which affects the transport of Digoxin |
CTD |
PMID:20510202 |
|
NCBI chr14:13,644,891...13,852,829
Ensembl chr14:13,542,647...13,742,727
|
|
|
G |
SCT |
secretin |
decreases abundance |
EXP |
SCT protein results in decreased abundance of Lactic Acid |
CTD |
PMID:2418308 |
|
|
|
|
G |
SOD1 |
superoxide dismutase 1 |
affects response to substance |
EXP |
SOD1 protein affects the susceptibility to Nafenopin |
CTD |
PMID:6333936 |
|
NCBI chr31:26,540,291...26,544,212
Ensembl chr31:26,486,274...26,662,815
|
|
|
G |
P2RY2 |
purinergic receptor P2Y2 |
multiple interactions |
EXP |
[Uridine Triphosphate results in increased activity of P2RY2 protein] which results in increased abundance of Cyclic AMP; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [[Uridine Triphosphate results in increased activity of P2RY2 protein] which results in increased abundance of Cyclic AMP] |
CTD |
PMID:10604969 |
|
NCBI chr21:24,987,568...25,009,754
Ensembl chr21:24,992,848...24,996,059
|
|
|
G |
CDIPT |
CDP-diacylglycerol--inositol 3-phosphatidyltransferase |
multiple interactions |
EXP |
[delta-hexachlorocyclohexane results in decreased activity of CDIPT protein] which results in decreased abundance of Cytidine Monophosphate; [Hexachlorocyclohexane affects the activity of CDIPT protein] which results in decreased abundance of Cytidine Monophosphate; [Inositol promotes the reaction [CDIPT protein results in increased metabolism of Cytidine Diphosphate Diglycerides]] which results in increased abundance of Cytidine Monophosphate |
CTD |
PMID:2579070 |
|
NCBI chr 6:17,910,141...17,914,573
Ensembl chr 6:17,910,192...17,914,653
|
|
|
G |
KCNH2 |
potassium voltage-gated channel subfamily H member 2 |
multiple interactions |
EXP |
Cisapride binds to and results in decreased activity of KCNH2 protein |
CTD |
PMID:12388285 |
|
NCBI chr16:15,009,031...15,041,786
Ensembl chr16:15,009,031...15,041,504
|
|
|
G |
ALPI |
alkaline phosphatase, intestinal |
increases chemical synthesis |
EXP |
ALPI protein results in increased chemical synthesis of nitrophenylphosphate |
CTD |
PMID:1495895 |
|
NCBI chr25:44,107,418...44,110,947
|
|
|
G |
P2RY2 |
purinergic receptor P2Y2 |
multiple interactions |
EXP |
pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [[Uridine Triphosphate results in increased activity of P2RY2 protein] which results in increased abundance of Arachidonic Acid]; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [[Uridine Triphosphate results in increased activity of P2RY2 protein] which results in increased abundance of Cyclic AMP] |
CTD |
PMID:10604969 |
|
NCBI chr21:24,987,568...25,009,754
Ensembl chr21:24,992,848...24,996,059
|
|
|
G |
NR1I2 |
nuclear receptor subfamily 1 group I member 2 |
increases activity |
EXP |
Omeprazole results in increased activity of NR1I2 protein |
CTD |
PMID:27732639 |
|
NCBI chr33:23,444,367...23,456,405
Ensembl chr33:23,432,690...23,455,347
|
|
G |
SLC22A6 |
solute carrier family 22 member 6 |
multiple interactions |
EXP |
[Omeprazole results in decreased activity of SLC22A6 protein] which results in decreased uptake of Indican |
CTD |
PMID:36243147 |
|
NCBI chr18:53,736,669...53,745,001
Ensembl chr18:53,736,959...53,744,396
|
|
|
G |
CFTR |
CF transmembrane conductance regulator |
decreases activity |
EXP |
5-nitro-2-(3-phenylpropylamino)benzoic acid results in decreased activity of CFTR protein |
CTD |
PMID:15496164 |
|
NCBI chr14:56,290,417...56,452,919
Ensembl chr14:56,290,275...56,453,977
|
|
|
G |
NR1I2 |
nuclear receptor subfamily 1 group I member 2 |
increases activity |
EXP |
6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased activity of NR1I2 protein |
CTD |
PMID:27732639 |
|
NCBI chr33:23,444,367...23,456,405
Ensembl chr33:23,432,690...23,455,347
|
|
G |
NR1I3 |
nuclear receptor subfamily 1 group I member 3 |
increases activity |
EXP |
6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased activity of NR1I3 protein mutant form |
CTD |
PMID:21778469 |
|
NCBI chr38:21,252,874...21,257,951
Ensembl chr38:21,253,089...21,258,827
|
|
|
G |
CFTR |
CF transmembrane conductance regulator |
multiple interactions |
EXP |
[1-Methyl-3-isobutylxanthine co-treated with 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP] results in increased activity of CFTR protein |
CTD |
PMID:15161604 |
|
NCBI chr14:56,290,417...56,452,919
Ensembl chr14:56,290,275...56,453,977
|
|
|
G |
CPNE6 |
copine 6 |
increases reduction |
EXP |
DHRS4 protein results in increased reduction of 9-cis-retinal |
CTD |
PMID:17827741 |
|
NCBI chr 8:4,046,532...4,058,498
Ensembl chr 8:4,046,544...4,084,744
|
|
|
G |
CPNE6 |
copine 6 |
increases reduction |
EXP |
DHRS4 protein results in increased reduction of acenaphthenequinone |
CTD |
PMID:17827741 |
|
NCBI chr 8:4,046,532...4,058,498
Ensembl chr 8:4,046,544...4,084,744
|
|
|
G |
ALPI |
alkaline phosphatase, intestinal |
increases chemical synthesis |
EXP |
ALPI protein results in increased chemical synthesis of acetophenone |
CTD |
PMID:1495895 |
|
NCBI chr25:44,107,418...44,110,947
|
|
|
G |
NR1I2 |
nuclear receptor subfamily 1 group I member 2 |
increases activity |
EXP |
2-acetyltributylcitrate results in increased activity of NR1I2 protein |
CTD |
PMID:21742782 |
|
NCBI chr33:23,444,367...23,456,405
Ensembl chr33:23,432,690...23,455,347
|
|
|
G |
KCNJ3 |
potassium inwardly rectifying channel subfamily J member 3 |
multiple interactions |
EXP |
Acetylcholine promotes the reaction [[KCNJ3 protein co-treated with KCNJ6 protein] results in increased transport of Potassium] |
CTD |
PMID:10666054 |
|
NCBI chr36:1,354,686...1,496,397
Ensembl chr36:1,354,678...1,493,766
|
|
G |
KCNJ6 |
potassium inwardly rectifying channel subfamily J member 6 |
multiple interactions |
EXP |
Acetylcholine promotes the reaction [[KCNJ3 protein co-treated with KCNJ6 protein] results in increased transport of Potassium] |
CTD |
PMID:10666054 |
|
NCBI chr31:32,752,585...33,010,999
Ensembl chr31:32,755,899...32,934,478
|
|
G |
MAPK14 |
mitogen-activated protein kinase 14 |
multiple interactions |
EXP |
Acetylcholine results in increased phosphorylation of and results in increased activity of MAPK14 protein |
CTD |
PMID:9688607 |
|
NCBI chr12:5,145,647...5,221,558
Ensembl chr12:5,146,037...5,220,603
|
|
|
G |
PTGS1 |
prostaglandin-endoperoxide synthase 1 |
decreases activity |
EXP |
Aspirin results in decreased activity of PTGS1 protein alternative form |
CTD |
PMID:12242329 |
|
NCBI chr 9:60,195,118...60,216,847
Ensembl chr 9:60,195,124...60,216,819
|
|
|
G |
INS |
insulin |
decreases abundance multiple interactions |
EXP |
INS protein results in decreased abundance of Glucose [INS protein co-treated with Glucose] results in decreased abundance of Potassium; [INS protein co-treated with Glucose] results in increased susceptibility to Digoxin; [INS protein co-treated with Glucose] results in increased uptake of Digoxin |
CTD |
PMID:140932 PMID:1013176 PMID:1646414 |
|
NCBI chr18:46,324,047...46,324,933
Ensembl chr18:46,324,041...46,325,122
|
|
|
G |
AGT |
angiotensinogen |
increases abundance |
EXP |
AGT results in increased abundance of Aldosterone |
CTD |
PMID:2831029 |
|
NCBI chr 4:8,681,192...8,694,059
Ensembl chr 4:8,683,798...8,693,880
|
|
G |
POMC |
proopiomelanocortin |
increases abundance |
EXP |
POMC protein results in increased abundance of Aldosterone |
CTD |
PMID:2831029 |
|
NCBI chr17:19,431,396...19,438,247
Ensembl chr17:19,431,585...19,434,440
|
|
|
G |
CASP3 |
caspase 3 |
increases activity |
EXP |
Tretinoin results in increased activity of CASP3 protein |
CTD |
PMID:16953078 |
|
NCBI chr16:45,920,074...45,940,507
Ensembl chr16:45,920,071...45,940,505
|
|
G |
CLDN1 |
claudin 1 |
multiple interactions increases expression |
EXP |
CYP26A1 protein inhibits the reaction [Tretinoin results in increased expression of CLDN1 mRNA] Tretinoin results in increased expression of CLDN1 mRNA; Tretinoin results in increased expression of CLDN1 protein |
CTD |
PMID:17035595 |
|
NCBI chr34:22,303,058...22,319,101
Ensembl chr34:22,303,850...22,319,033
|
|
G |
CLDN4 |
claudin 4 |
increases expression multiple interactions |
EXP |
Tretinoin results in increased expression of CLDN4 mRNA; Tretinoin results in increased expression of CLDN4 protein CYP26A1 protein inhibits the reaction [Tretinoin results in increased expression of CLDN4 mRNA] |
CTD |
PMID:17035595 |
|
NCBI chr 6:6,492,706...6,506,750
Ensembl chr 6:6,493,513...6,494,145
|
|
G |
CYP26A1 |
cytochrome P450 family 26 subfamily A member 1 |
increases degradation multiple interactions |
EXP |
CYP26A1 protein results in increased degradation of Tretinoin CYP26A1 protein inhibits the reaction [Tretinoin results in increased expression of CLDN1 mRNA]; CYP26A1 protein inhibits the reaction [Tretinoin results in increased expression of CLDN4 mRNA]; CYP26A1 protein inhibits the reaction [Tretinoin results in increased expression of OCLN mRNA]; CYP26A1 protein inhibits the reaction [Tretinoin results in increased expression of TJP1 mRNA] |
CTD |
PMID:17035595 |
|
NCBI chr28:7,423,955...7,432,359
Ensembl chr28:7,428,772...7,432,370
|
|
G |
NOS3 |
nitric oxide synthase 3 |
increases expression |
EXP |
Tretinoin results in increased expression of NOS3 mRNA; Tretinoin results in increased expression of NOS3 protein |
CTD |
PMID:17267746 |
|
NCBI chr16:15,054,196...15,072,454
Ensembl chr16:15,011,344...15,072,277
|
|
G |
OCLN |
occludin |
multiple interactions increases expression |
EXP |
CYP26A1 protein inhibits the reaction [Tretinoin results in increased expression of OCLN mRNA] Tretinoin results in increased expression of OCLN mRNA; Tretinoin results in increased expression of OCLN protein |
CTD |
PMID:17035595 |
|
NCBI chr 2:54,500,299...54,545,430
Ensembl chr 2:54,500,299...54,545,430
|
|
G |
TJP1 |
tight junction protein 1 |
increases expression multiple interactions |
EXP |
Tretinoin results in increased expression of TJP1 mRNA; Tretinoin results in increased expression of TJP1 protein CYP26A1 protein inhibits the reaction [Tretinoin results in increased expression of TJP1 mRNA] |
CTD |
PMID:17035595 |
|
NCBI chr 3:38,997,122...39,076,617
Ensembl chr 3:38,997,076...39,241,574
|
|
|
G |
ABCB1 |
ATP binding cassette subfamily B member 1 |
multiple interactions |
EXP |
allicin inhibits the reaction [ABCB1 protein results in increased secretion of Ritonavir] |
CTD |
PMID:15266218 |
|
NCBI chr14:13,644,891...13,852,829
Ensembl chr14:13,542,647...13,742,727
|
|
|
G |
SLC8A1 |
solute carrier family 8 member A1 |
decreases activity |
EXP |
Amiodarone results in decreased activity of SLC8A1 protein |
CTD |
PMID:15288574 |
|
NCBI chr17:32,004,207...32,381,399
Ensembl chr17:32,005,245...32,307,700
|
|
|
G |
REN |
renin |
increases expression |
EXP |
Amlodipine results in increased expression of REN protein |
CTD |
PMID:10218729 |
|
NCBI chr38:744,540...766,998
Ensembl chr38:744,614...755,012
|
|
|
G |
ADRB1 |
adrenoceptor beta 1 |
multiple interactions |
EXP |
amosulalol binds to and results in decreased activity of ADRB1 protein |
CTD |
PMID:6129981 |
|
NCBI chr28:24,908,224...24,909,684
Ensembl chr28:24,908,224...24,909,684
|
|
G |
ADRB2 |
adrenoceptor beta 2 |
multiple interactions |
EXP |
amosulalol binds to and results in decreased activity of ADRB2 protein |
CTD |
PMID:6129981 |
|
NCBI chr 4:60,048,502...60,050,447
Ensembl chr 4:59,941,517...60,050,298
|
|
|
G |
IL6 |
interleukin 6 |
multiple interactions increases expression |
EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Amphotericin B results in increased expression of IL6 protein] |
CTD |
PMID:24105867 |
|
NCBI chr14:36,474,268...36,478,519
Ensembl chr14:36,473,394...36,478,519
|
|
G |
PRKACB |
protein kinase cAMP-activated catalytic subunit beta |
increases expression multiple interactions |
EXP |
Amphotericin B results in increased expression of PRKACG protein N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Amphotericin B results in increased expression of PRKACG protein] |
CTD |
PMID:24105867 |
|
NCBI chr 6:63,615,445...63,729,386
Ensembl chr 6:63,618,323...63,730,146
|
|
G |
REN |
renin |
decreases secretion |
EXP |
Amphotericin B results in decreased secretion of REN protein |
CTD |
PMID:7391978 |
|
NCBI chr38:744,540...766,998
Ensembl chr38:744,614...755,012
|
|
G |
TNF |
tumor necrosis factor |
increases expression |
EXP |
Amphotericin B results in increased expression of TNF protein |
CTD |
PMID:24105867 |
|
NCBI chr12:1,074,561...1,076,425
Ensembl chr12:1,074,552...1,076,425
|
|
|
G |
CLDN4 |
claudin 4 |
multiple interactions |
EXP |
pyrazolanthrone inhibits the reaction [Hydrogen Peroxide results in increased expression of CLDN4 protein]; pyrazolanthrone inhibits the reaction [Sodium Chloride results in increased expression of CLDN4 protein] |
CTD |
PMID:23816505 |
|
NCBI chr 6:6,492,706...6,506,750
Ensembl chr 6:6,493,513...6,494,145
|
|
G |
JUN |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
EXP |
pyrazolanthrone inhibits the reaction [Sodium Chloride promotes the reaction [SP1 protein binds to JUN protein]] |
CTD |
PMID:23816505 |
|
NCBI chr 5:50,966,698...50,968,939
|
|
G |
MAPK8 |
mitogen-activated protein kinase 8 |
multiple interactions |
EXP |
pyrazolanthrone inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [Sodium Chloride results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:23816505 |
|
NCBI chr28:323,361...410,367
Ensembl chr28:368,513...406,401
|
|
G |
MAPK9 |
mitogen-activated protein kinase 9 |
multiple interactions |
EXP |
pyrazolanthrone inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK9 protein]; pyrazolanthrone inhibits the reaction [Sodium Chloride results in increased phosphorylation of MAPK9 protein] |
CTD |
PMID:23816505 |
|
NCBI chr11:1,443,528...1,480,501
Ensembl chr11:1,443,547...1,478,119
|
|
G |
SP1 |
Sp1 transcription factor |
multiple interactions |
EXP |
pyrazolanthrone inhibits the reaction [Sodium Chloride promotes the reaction [SP1 protein binds to JUN protein]]; pyrazolanthrone inhibits the reaction [Sodium Chloride results in increased expression of SP1 protein] |
CTD |
PMID:23816505 |
|
NCBI chr27:1,802,587...1,861,187
Ensembl chr27:1,805,184...1,847,226
|
|
|
G |
PTGS1 |
prostaglandin-endoperoxide synthase 1 |
decreases activity |
EXP |
Antipyrine results in decreased activity of PTGS1 protein alternative form |
CTD |
PMID:12242329 |
|
NCBI chr 9:60,195,118...60,216,847
Ensembl chr 9:60,195,124...60,216,819
|
|
|
G |
P2RY2 |
purinergic receptor P2Y2 |
multiple interactions |
EXP |
[Uridine Triphosphate results in increased activity of P2RY2 protein] which results in increased abundance of Arachidonic Acid; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [[Uridine Triphosphate results in increased activity of P2RY2 protein] which results in increased abundance of Arachidonic Acid] |
CTD |
PMID:10604969 |
|
NCBI chr21:24,987,568...25,009,754
Ensembl chr21:24,992,848...24,996,059
|
|
|
G |
HSP70 |
heat shock protein 70 |
increases expression multiple interactions |
EXP |
arsenite results in increased expression of HSP70 mRNA HSP70 protein affects the reaction [arsenite inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]]; HSP70 protein affects the reaction [arsenite inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]]; HSP70 protein affects the reaction [arsenite inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]; HSP70 protein affects the reaction [arsenite inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of RELA protein]] |
CTD |
PMID:32899721 |
|
NCBI chr12:1,285,282...1,287,670
|
|
G |
IL1B |
interleukin 1 beta |
multiple interactions |
EXP |
arsenite affects the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; HSP70 protein affects the reaction [arsenite inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]] |
CTD |
PMID:32899721 |
|
NCBI chr17:37,019,329...37,033,388
Ensembl chr17:37,019,329...37,024,458
|
|
G |
IL6 |
interleukin 6 |
multiple interactions |
EXP |
arsenite inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; HSP70 protein affects the reaction [arsenite inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]] |
CTD |
PMID:32899721 |
|
NCBI chr14:36,474,268...36,478,519
Ensembl chr14:36,473,394...36,478,519
|
|
G |
RELA |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
arsenite inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of RELA protein]; HSP70 protein affects the reaction [arsenite inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of RELA protein]] |
CTD |
PMID:32899721 |
|
NCBI chr18:51,550,003...51,558,861
Ensembl chr18:51,550,040...51,558,875
|
|
G |
TNF |
tumor necrosis factor |
multiple interactions |
EXP |
arsenite inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; HSP70 protein affects the reaction [arsenite inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]] |
CTD |
PMID:32899721 |
|
NCBI chr12:1,074,561...1,076,425
Ensembl chr12:1,074,552...1,076,425
|
|
|
G |
MAPK1 |
mitogen-activated protein kinase 1 |
multiple interactions |
EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Arsenic Trioxide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Arsenic Trioxide results in increased phosphorylation of and results in increased activity of MAPK1 protein |
CTD |
PMID:23236503 |
|
NCBI chr26:31,013,607...31,132,998
Ensembl chr26:31,013,607...31,132,998
|
|
G |
MAPK3 |
mitogen-activated protein kinase 3 |
multiple interactions |
EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Arsenic Trioxide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Arsenic Trioxide results in increased phosphorylation of and results in increased activity of MAPK3 protein |
CTD |
PMID:23236503 |
|
NCBI chr 6:18,109,184...18,115,728
Ensembl chr 6:18,109,222...18,114,425
|
|
G |
SLC9A1 |
solute carrier family 9 member A1 |
increases expression |
EXP |
Arsenic Trioxide results in increased expression of SLC9A1 protein |
CTD |
PMID:23236503 |
|
NCBI chr 2:73,054,742...73,103,364
Ensembl chr 2:73,054,742...73,103,364
|
|
|
G |
REN |
renin |
multiple interactions |
EXP |
Atenolol inhibits the reaction [Isoproterenol results in increased activity of REN protein] |
CTD |
PMID:6103674 |
|
NCBI chr38:744,540...766,998
Ensembl chr38:744,614...755,012
|
|
|
G |
ACHE |
acetylcholinesterase |
multiple interactions |
EXP |
[Obidoxime Chloride co-treated with Atropine] inhibits the reaction [Sarin results in decreased activity of ACHE protein]; [Obidoxime Chloride co-treated with Atropine] inhibits the reaction [Soman results in decreased activity of ACHE protein]; [Obidoxime Chloride co-treated with Atropine] inhibits the reaction [VX results in decreased activity of ACHE protein] |
CTD |
PMID:16915560 |
|
NCBI chr 6:8,874,747...8,879,926
Ensembl chr 6:8,873,584...8,879,702
|
|
G |
SCT |
secretin |
multiple interactions |
EXP |
Atropine inhibits the reaction [SCT protein results in increased abundance of Bicarbonates] |
CTD |
PMID:3562434 |
|
|
|
|
G |
DES |
desmin |
decreases expression |
EXP |
benazepril results in decreased expression of DES mRNA |
CTD |
PMID:20137276 |
|
NCBI chr37:25,933,525...25,939,910
Ensembl chr37:25,933,455...25,940,985
|
|
|
G |
CYP2E1 |
cytochrome P450 family 2 subfamily E member 1 |
affects metabolic processing |
EXP |
CYP2E1 protein affects the metabolism of Benzyl Alcohol |
CTD |
PMID:8592870 |
|
NCBI chr28:41,079,164...41,089,188
Ensembl chr28:41,035,025...41,122,754
|
|
|
G |
CYP1A1 |
cytochrome P450 family 1 subfamily A member 1 |
increases activity |
EXP |
beta-Naphthoflavone results in increased activity of CYP1A1 protein |
CTD |
PMID:3929785 |
|
NCBI chr30:37,793,277...37,799,535
Ensembl chr30:37,793,508...37,796,866
|
|
|
G |
NR1I3 |
nuclear receptor subfamily 1 group I member 3 |
increases activity |
EXP |
Diethylhexyl Phthalate results in increased activity of NR1I3 protein |
CTD |
PMID:27732639 |
|
NCBI chr38:21,252,874...21,257,951
Ensembl chr38:21,253,089...21,258,827
|
|
|
G |
ABCB11 |
ATP binding cassette subfamily B member 11 |
decreases localization |
EXP |
blebbistatin results in decreased localization of ABCB11 protein |
CTD |
PMID:15826951 |
|
NCBI chr36:13,742,895...13,835,312
Ensembl chr36:13,746,964...13,834,974
|
|
|
G |
CPNE6 |
copine 6 |
decreases activity |
EXP |
Sulfobromophthalein results in decreased activity of DHRS4 protein |
CTD |
PMID:17827741 |
|
NCBI chr 8:4,046,532...4,058,498
Ensembl chr 8:4,046,544...4,084,744
|
|
G |
SLCO1B2 |
solute carrier organic anion transporter family member 1B2 |
increases transport |
EXP |
SLCO1B3 protein results in increased transport of Sulfobromophthalein |
CTD |
PMID:20079461 |
|
NCBI chr27:26,411,008...26,496,174
Ensembl chr27:26,411,010...26,470,989
|
|
|
G |
CYP2D15 |
cytochrome P450 family 2 subfamily D member 15 |
affects metabolic processing |
EXP |
CYP2D6 protein affects the metabolism of bufuralol |
CTD |
PMID:15801540 |
|
NCBI chr10:23,255,259...23,259,380
Ensembl chr10:23,255,249...23,259,298
|
|
|
G |
ABCC1 |
ATP binding cassette subfamily C member 1 |
affects export |
EXP |
ABCC1 protein affects the export of calcein AM |
CTD |
PMID:12516967 |
|
NCBI chr 6:27,855,702...27,950,140
Ensembl chr 6:27,855,702...27,989,331
|
|
|
G |
BCL2 |
BCL2 apoptosis regulator |
affects expression |
EXP |
Calcitriol affects the expression of BCL2 protein |
CTD |
PMID:16080513 |
|
NCBI chr 1:13,733,849...13,900,653
Ensembl chr 1:13,731,406...13,900,658
|
|
|
G |
CASP3 |
caspase 3 |
multiple interactions increases activity |
EXP |
Diosgenin inhibits the reaction [Calcium Oxalate results in increased activity of CASP3 protein] |
CTD |
PMID:25446497 |
|
NCBI chr16:45,920,074...45,940,507
Ensembl chr16:45,920,071...45,940,505
|
|
G |
CASP9 |
caspase 9 |
increases activity multiple interactions |
EXP |
Calcium Oxalate results in increased activity of CASP9 protein Diosgenin inhibits the reaction [Calcium Oxalate results in increased activity of CASP9 protein] |
CTD |
PMID:25446497 |
|
NCBI chr 2:82,033,759...82,076,710
Ensembl chr 2:82,031,563...82,090,484
|
|
G |
TJP1 |
tight junction protein 1 |
multiple interactions decreases expression |
EXP |
Docetaxel inhibits the reaction [Calcium Oxalate results in decreased expression of TJP1 protein]; Phalloidine inhibits the reaction [Calcium Oxalate results in decreased expression of TJP1 protein] |
CTD |
PMID:34147488 PMID:36349591 |
|
NCBI chr 3:38,997,122...39,076,617
Ensembl chr 3:38,997,076...39,241,574
|
|
|
G |
CCL17 |
C-C motif chemokine ligand 17 |
multiple interactions |
EXP |
[Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of CCL17 mRNA]; [Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] results in increased methylation of CCL17 promoter |
CTD |
PMID:33763461 |
|
NCBI chr 2:59,001,463...59,014,347
Ensembl chr 2:59,001,464...59,005,230
|
|
G |
CCL2 |
C-C motif chemokine ligand 2 |
multiple interactions |
EXP |
[Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of CCL2 mRNA]; [Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] results in increased methylation of CCL2 promoter |
CTD |
PMID:33763461 |
|
NCBI chr 9:39,008,187...39,009,932
|
|
G |
IL13 |
interleukin 13 |
multiple interactions |
EXP |
[Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of CCL17 mRNA]; [Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of CCL2 mRNA]; [Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of IL31RA mRNA]; [Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of TSLP mRNA] |
CTD |
PMID:33763461 |
|
NCBI chr11:20,957,870...20,961,391
Ensembl chr11:20,958,464...20,961,388
|
|
G |
IL31 |
interleukin 31 |
multiple interactions |
EXP |
[Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of CCL17 mRNA]; [Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of CCL2 mRNA]; [Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of IL31RA mRNA]; [Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of TSLP mRNA] |
CTD |
PMID:33763461 |
|
NCBI chr26:7,173,151...7,175,195
Ensembl chr26:7,172,451...7,175,195
|
|
G |
IL31RA |
interleukin 31 receptor A |
multiple interactions |
EXP |
[Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of IL31RA mRNA]; [Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] results in increased methylation of IL31RA promoter |
CTD |
PMID:33763461 |
|
NCBI chr 2:43,113,194...43,198,200
Ensembl chr 2:43,144,071...43,193,293
|
|
G |
IL4 |
interleukin 4 |
multiple interactions |
EXP |
[Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of CCL17 mRNA]; [Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of CCL2 mRNA]; [Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of IL31RA mRNA]; [Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of TSLP mRNA] |
CTD |
PMID:33763461 |
|
NCBI chr11:20,972,693...20,981,539
Ensembl chr11:20,972,690...20,981,534
|
|
G |
TSLP |
thymic stromal lymphopoietin |
multiple interactions |
EXP |
[Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of TSLP mRNA]; [Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] results in increased methylation of TSLP promoter |
CTD |
PMID:33763461 |
|
NCBI chr 3:1,502,469...1,507,696
Ensembl chr 3:1,503,188...1,507,696
|
|
|
G |
HTR1B |
5-hydroxytryptamine receptor 1B |
multiple interactions |
EXP |
HTR1B protein promotes the reaction [donitriptan results in decreased susceptibility to Capsaicin] |
CTD |
PMID:16880765 |
|
NCBI chr12:38,659,088...38,659,546
|
|
G |
TRPV1 |
transient receptor potential cation channel subfamily V member 1 |
multiple interactions increases activity |
EXP |
JYL 1421 inhibits the reaction [Capsaicin results in increased activity of TRPV1 protein] |
CTD |
PMID:17392452 |
|
NCBI chr 9:47,404,987...47,443,871
Ensembl chr 9:47,404,972...47,431,926
|
|
|
G |
MGMT |
O-6-methylguanine-DNA methyltransferase |
decreases response to substance multiple interactions |
EXP |
MGMT protein mutant form results in decreased susceptibility to Carmustine; MGMT protein results in decreased susceptibility to Carmustine MGMT protein mutant form results in decreased susceptibility to [Carmustine co-treated with O(6)-benzylguanine] |
CTD |
PMID:14617759 PMID:15053863 |
|
NCBI chr28:38,204,611...38,427,482
Ensembl chr28:38,204,610...38,427,380
|
|
|
G |
HSP70 |
heat shock protein 70 |
multiple interactions |
EXP |
carvacrol promotes the reaction [sodium arsenite results in increased expression of HSP70 protein] |
CTD |
PMID:31940135 |
|
NCBI chr12:1,285,282...1,287,670
|
|
|
G |
CASP3 |
caspase 3 |
decreases activity |
EXP |
Carvedilol results in decreased activity of CASP3 protein |
CTD |
PMID:12875697 |
|
NCBI chr16:45,920,074...45,940,507
Ensembl chr16:45,920,071...45,940,505
|
|
G |
FAS |
Fas cell surface death receptor |
decreases expression |
EXP |
Carvedilol results in decreased expression of FAS |
CTD |
PMID:12875697 |
|
NCBI chr26:38,738,811...38,763,298
Ensembl chr26:38,737,611...38,763,321
|
|
G |
FASLG |
Fas ligand |
decreases expression |
EXP |
Carvedilol results in decreased expression of FASLG |
CTD |
PMID:12875697 |
|
NCBI chr 7:26,335,837...26,344,224
Ensembl chr 7:26,335,846...26,344,224
|
|
G |
NT5E |
5'-nucleotidase ecto |
increases activity |
EXP |
Carvedilol results in increased activity of NT5E protein |
CTD |
PMID:15148268 |
|
NCBI chr12:45,491,028...45,520,019
Ensembl chr12:45,491,733...45,518,405
|
|
G |
RYR2 |
ryanodine receptor 2 |
multiple interactions |
EXP |
Carvedilol results in decreased oxidation of and results in increased stability of RYR2 protein |
CTD |
PMID:17448375 |
|
NCBI chr 4:2,371,868...2,908,132
Ensembl chr 4:2,373,114...2,907,875
|
|
|
G |
ACE |
angiotensin I converting enzyme |
decreases activity |
EXP |
ceronapril results in decreased activity of ACE protein |
CTD |
PMID:1812274 |
|
NCBI chr 9:11,497,182...11,516,362
Ensembl chr 9:11,497,182...11,516,358
|
|
|
G |
SCT |
secretin |
multiple interactions |
EXP |
[Ceruletide co-treated with SCT protein] results in increased abundance of Bicarbonates |
CTD |
PMID:3562434 |
|
|
|
|
G |
AGT |
angiotensinogen |
decreases expression |
EXP |
Cilazapril results in decreased expression of AGT protein |
CTD |
PMID:2419701 |
|
NCBI chr 4:8,681,192...8,694,059
Ensembl chr 4:8,683,798...8,693,880
|
|
G |
REN |
renin |
increases activity |
EXP |
Cilazapril results in increased activity of REN protein |
CTD |
PMID:2419701 |
|
NCBI chr38:744,540...766,998
Ensembl chr38:744,614...755,012
|
|
|
G |
MYC |
MYC proto-oncogene, bHLH transcription factor |
decreases expression |
EXP |
Cilostazol results in decreased expression of MYC mRNA |
CTD |
PMID:19545562 |
|
NCBI chr13:25,200,772...25,205,309
Ensembl chr13:25,200,577...25,205,309
|
|
|
G |
SLC22A2 |
solute carrier family 22 member 2 |
decreases activity |
EXP |
Cimetidine results in decreased activity of SLC22A2 protein |
CTD |
PMID:36669674 |
|
NCBI chr 1:49,327,621...49,348,435
Ensembl chr 1:49,327,296...49,348,435
|
|
|
G |
KCNH2 |
potassium voltage-gated channel subfamily H member 2 |
multiple interactions |
EXP |
Cisapride binds to and results in decreased activity of KCNH2 protein |
CTD |
PMID:12388285 |
|
NCBI chr16:15,009,031...15,041,786
Ensembl chr16:15,009,031...15,041,504
|
|
|
G |
ACAA2 |
acetyl-CoA acyltransferase 2 |
increases expression |
EXP |
Clofibrate results in increased expression of ACAA2 mRNA |
CTD |
PMID:19952500 |
|
NCBI chr 7:79,028,636...79,057,720
|
|
G |
ACADVL |
acyl-CoA dehydrogenase very long chain |
increases expression |
EXP |
Clofibrate results in increased expression of ACADVL protein |
CTD |
PMID:19952500 |
|
NCBI chr 5:32,189,191...32,194,255
Ensembl chr 5:32,186,502...32,327,990
|
|
G |
AGXT |
alanine--glyoxylate and serine--pyruvate aminotransferase |
decreases expression |
EXP |
Clofibrate results in decreased expression of AGXT protein |
CTD |
PMID:19952500 |
|
NCBI chr25:50,968,291...50,976,089
|
|
G |
AHCY |
adenosylhomocysteinase |
decreases expression |
EXP |
Clofibrate results in decreased expression of AHCY protein |
CTD |
PMID:19952500 |
|
NCBI chr24:23,410,553...23,423,494
Ensembl chr24:23,411,140...23,419,767
|
|
G |
ASL |
argininosuccinate lyase |
increases expression |
EXP |
Clofibrate results in increased expression of ASL protein |
CTD |
PMID:19952500 |
|
NCBI chr 6:768,522...779,144
Ensembl chr 6:730,358...779,424
|
|
G |
ASS1 |
argininosuccinate synthase 1 |
decreases expression |
EXP |
Clofibrate results in decreased expression of ASS1 protein |
CTD |
PMID:19952500 |
|
NCBI chr 9:53,425,228...53,478,007
Ensembl chr 9:53,425,448...53,477,904
|
|
G |
CPS1 |
carbamoyl-phosphate synthase 1 |
increases expression |
EXP |
Clofibrate results in increased expression of CPS1 protein |
CTD |
PMID:19952500 |
|
NCBI chr37:18,308,164...18,428,487
Ensembl chr37:18,143,986...18,427,697
|
|
G |
CPT2 |
carnitine palmitoyltransferase 2 |
increases expression |
EXP |
Clofibrate results in increased expression of CPT2 mRNA |
CTD |
PMID:19952500 |
|
NCBI chr 5:55,718,209...55,786,175
Ensembl chr 5:55,718,510...55,744,809
|
|
G |
CYP1A2 |
cytochrome P450 family 1 subfamily A member 2 |
decreases expression |
EXP |
Clofibrate results in decreased expression of CYP1A2 mRNA |
CTD |
PMID:19952500 |
|
NCBI chr30:37,818,400...37,824,192
Ensembl chr30:37,799,140...37,824,135
|
|
G |
CYP2A13 |
cytochrome P450 family 2 subfamily A polypeptide 13 |
decreases expression |
EXP |
Clofibrate results in decreased expression of CYP2A13 mRNA |
CTD |
PMID:19952500 |
|
NCBI chr 1:112,932,246...112,938,248
Ensembl chr 1:112,931,985...112,938,350
|
|
G |
CYP2B6 |
cytochrome P450 2B11 |
decreases expression |
EXP |
Clofibrate results in decreased expression of CYP2B6 mRNA |
CTD |
PMID:19952500 |
|
NCBI chr 1:112,817,561...112,833,294
Ensembl chr 1:112,816,502...112,833,293
|
|
G |
CYP2C18 |
cytochrome P450 2C21 |
decreases expression |
EXP |
Clofibrate results in decreased expression of CYP2C18 mRNA |
CTD |
PMID:19952500 |
|
NCBI chr28:8,727,010...8,750,427
Ensembl chr28:8,727,019...8,750,587
|
|
G |
CYP2E1 |
cytochrome P450 family 2 subfamily E member 1 |
increases expression |
EXP |
Clofibrate results in increased expression of CYP2E1 protein |
CTD |
PMID:19952500 |
|
NCBI chr28:41,079,164...41,089,188
Ensembl chr28:41,035,025...41,122,754
|
|
G |
CYP3A12 |
cytochrome P-450 3A12 |
decreases expression |
EXP |
Clofibrate results in decreased expression of CYP3A12 mRNA |
CTD |
PMID:19952500 |
|
|
|
G |
CYP3A26 |
cytochrome P450 3A26 |
decreases expression |
EXP |
Clofibrate results in decreased expression of CYP3A26 mRNA |
CTD |
PMID:19952500 |
|
NCBI chr 6:9,777,663...9,815,345
Ensembl chr 6:9,777,659...9,869,352
|
|
G |
CYP4A11 |
cytochrome P450, family 4, subfamily A, polypeptide 11 |
increases expression |
EXP |
Clofibrate results in increased expression of CYP4A11 mRNA |
CTD |
PMID:19952500 |
|
NCBI chr15:13,663,337...13,676,350
Ensembl chr15:13,604,130...13,676,344
|
|
G |
DLST |
dihydrolipoamide S-succinyltransferase |
increases expression |
EXP |
Clofibrate results in increased expression of DLST protein |
CTD |
PMID:19952500 |
|
NCBI chr 8:48,003,730...48,025,001
Ensembl chr 8:48,002,211...48,024,999
|
|
G |
ECHS1 |
enoyl-CoA hydratase, short chain 1 |
increases expression |
EXP |
Clofibrate results in increased expression of ECHS1 protein |
CTD |
PMID:19952500 |
|
NCBI chr28:40,939,856...40,947,694
Ensembl chr28:40,939,961...40,946,167
|
|
G |
GDI1 |
GDP dissociation inhibitor 1 |
increases expression |
EXP |
Clofibrate results in increased expression of GDI1 protein |
CTD |
PMID:19952500 |
|
NCBI chr X:122,141,633...122,146,724
Ensembl chr X:122,141,566...122,146,824
|
|
G |
GSTA4 |
glutathione S-transferase alpha 4 |
decreases expression |
EXP |
Clofibrate results in decreased expression of GSTA4 mRNA |
CTD |
PMID:19952500 |
|
NCBI chr12:20,426,724...20,443,200
Ensembl chr12:20,426,726...20,443,200
|
|
G |
GSTK1 |
glutathione S-transferase kappa 1 |
decreases expression |
EXP |
Clofibrate results in decreased expression of GSTK1 mRNA |
CTD |
PMID:19952500 |
|
NCBI chr16:6,411,678...6,416,135
|
|
G |
GSTO1 |
glutathione S-transferase omega 1 |
decreases expression |
EXP |
Clofibrate results in decreased expression of GSTO1 mRNA |
CTD |
PMID:19952500 |
|
NCBI chr28:16,569,421...16,579,239
Ensembl chr28:16,569,066...16,619,880
|
|
G |
HADH |
hydroxyacyl-CoA dehydrogenase |
increases expression |
EXP |
Clofibrate results in increased expression of HADH mRNA |
CTD |
PMID:19952500 |
|
NCBI chr32:28,460,445...28,506,141
Ensembl chr32:28,460,193...28,531,280
|
|
G |
HSPD1 |
heat shock protein family D (Hsp60) member 1 |
increases expression |
EXP |
Clofibrate results in increased expression of HSPD1 protein |
CTD |
PMID:19952500 |
|
NCBI chr37:7,010,421...7,025,912
|
|
G |
KRT1 |
keratin 1 |
increases expression |
EXP |
Clofibrate results in increased expression of KRT1 protein |
CTD |
PMID:19952500 |
|
NCBI chr27:2,422,150...2,427,160
|
|
G |
KRT18 |
keratin 18 |
decreases expression |
EXP |
Clofibrate results in decreased expression of KRT18 protein |
CTD |
PMID:19952500 |
|
NCBI chr27:2,189,269...2,193,368
Ensembl chr27:2,189,269...2,193,368
|
|
G |
LOC474938 |
glutathione S-transferase A2 |
decreases expression |
EXP |
Clofibrate results in decreased expression of GSTA3 mRNA; Clofibrate results in decreased expression of GSTA3 protein |
CTD |
PMID:19952500 |
|
NCBI chr12:20,349,133...20,365,023
|
|
G |
LOC479912 |
glutathione S-transferase Mu 1 |
decreases expression |
EXP |
Clofibrate results in decreased expression of GSTM1 mRNA |
CTD |
PMID:19952500 |
|
NCBI chr 6:42,201,697...42,207,886
|
|
G |
MGST1 |
microsomal glutathione S-transferase 1 |
increases expression |
EXP |
Clofibrate results in increased expression of MGST1 mRNA |
CTD |
PMID:19952500 |
|
NCBI chr27:30,370,588...30,391,898
Ensembl chr27:30,370,594...30,391,778
|
|
G |
PC |
pyruvate carboxylase |
increases expression |
EXP |
Clofibrate results in increased expression of PC protein |
CTD |
PMID:19952500 |
|
NCBI chr18:50,406,994...50,507,677
Ensembl chr18:50,412,272...50,507,669
|
|
G |
PCK2 |
phosphoenolpyruvate carboxykinase 2, mitochondrial |
increases expression |
EXP |
Clofibrate results in increased expression of PCK2 protein |
CTD |
PMID:19952500 |
|
NCBI chr 8:4,099,016...4,107,870
Ensembl chr 8:4,098,671...4,107,865
|
|
G |
PRDX6 |
peroxiredoxin 6 |
decreases expression |
EXP |
Clofibrate results in decreased expression of PRDX6 protein |
CTD |
PMID:19952500 |
|
NCBI chr 7:25,663,238...25,675,855
Ensembl chr 7:25,663,579...25,675,754
|
|
G |
SELENBP1 |
selenium binding protein 1 |
decreases expression |
EXP |
Clofibrate results in decreased expression of SELENBP1 protein |
CTD |
PMID:19952500 |
|
NCBI chr17:60,410,727...60,418,770
Ensembl chr17:60,410,734...60,418,704
|
|
G |
SHMT1 |
serine hydroxymethyltransferase 1 |
decreases expression |
EXP |
Clofibrate results in decreased expression of SHMT1 protein |
CTD |
PMID:19952500 |
|
NCBI chr 5:41,221,531...41,248,653
Ensembl chr 5:41,221,562...41,253,166
|
|
G |
UGP2 |
UDP-glucose pyrophosphorylase 2 |
decreases expression |
EXP |
Clofibrate results in decreased expression of UGP2 protein |
CTD |
PMID:19952500 |
|
NCBI chr10:63,532,366...63,598,362
Ensembl chr10:63,533,171...63,597,452
|
|
G |
UQCRC1 |
ubiquinol-cytochrome c reductase core protein 1 |
increases expression |
EXP |
Clofibrate results in increased expression of UQCRC1 protein |
CTD |
PMID:19952500 |
|
NCBI chr20:40,507,767...40,515,854
Ensembl chr20:40,506,907...40,520,110
|
|
G |
UROC1 |
urocanate hydratase 1 |
decreases expression |
EXP |
Clofibrate results in decreased expression of UROC1 protein |
CTD |
PMID:19952500 |
|
NCBI chr20:676,624...717,109
Ensembl chr20:678,073...717,141
|
|
|
G |
INS |
insulin |
increases abundance |
EXP |
INS protein results in increased abundance of Adrenocorticotropic Hormone |
CTD |
PMID:1646414 |
|
NCBI chr18:46,324,047...46,324,933
Ensembl chr18:46,324,041...46,325,122
|
|
|
G |
CRH |
corticotropin releasing hormone |
increases abundance |
EXP |
CRH protein results in increased abundance of Hydrocortisone |
CTD |
PMID:2831029 |
|
NCBI chr29:15,831,944...15,840,560
Ensembl chr29:15,831,944...15,834,384
|
|
G |
INS |
insulin |
affects abundance multiple interactions |
EXP |
INS protein affects the abundance of Hydrocortisone Sodium affects the reaction [INS protein affects the abundance of Hydrocortisone] |
CTD |
PMID:1324617 |
|
NCBI chr18:46,324,047...46,324,933
Ensembl chr18:46,324,041...46,325,122
|
|
G |
POMC |
proopiomelanocortin |
increases abundance |
EXP |
POMC protein results in increased abundance of Hydrocortisone |
CTD |
PMID:2831029 |
|
NCBI chr17:19,431,396...19,438,247
Ensembl chr17:19,431,585...19,434,440
|
|
|
G |
CYP2B6 |
cytochrome P450 2B11 |
increases hydroxylation |
EXP |
CYP2B6 protein results in increased hydroxylation of Cyclophosphamide |
CTD |
PMID:16546968 |
|
NCBI chr 1:112,817,561...112,833,294
Ensembl chr 1:112,816,502...112,833,293
|
|
|
G |
CDIPT |
CDP-diacylglycerol--inositol 3-phosphatidyltransferase |
multiple interactions |
EXP |
[delta-hexachlorocyclohexane results in decreased activity of CDIPT protein] which results in decreased abundance of Cytidine Monophosphate; [Hexachlorocyclohexane affects the activity of CDIPT protein] which results in decreased abundance of Cytidine Monophosphate; [Inositol promotes the reaction [CDIPT protein results in increased metabolism of Cytidine Diphosphate Diglycerides]] which results in increased abundance of Cytidine Monophosphate |
CTD |
PMID:2579070 |
|
NCBI chr 6:17,910,141...17,914,573
Ensembl chr 6:17,910,192...17,914,653
|
|
|
G |
MAPK1 |
mitogen-activated protein kinase 1 |
increases phosphorylation |
EXP |
Sorbitol results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:12639917 |
|
NCBI chr26:31,013,607...31,132,998
Ensembl chr26:31,013,607...31,132,998
|
|
G |
MAPK3 |
mitogen-activated protein kinase 3 |
increases phosphorylation |
EXP |
Sorbitol results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:12639917 |
|
NCBI chr 6:18,109,184...18,115,728
Ensembl chr 6:18,109,222...18,114,425
|
|
|
G |
INS |
insulin |
multiple interactions decreases abundance |
EXP |
[INS protein co-treated with Glucose] results in decreased abundance of Potassium; [INS protein co-treated with Glucose] results in increased susceptibility to Digoxin; [INS protein co-treated with Glucose] results in increased uptake of Digoxin INS protein results in decreased abundance of Glucose |
CTD |
PMID:140932 PMID:1013176 PMID:1646414 |
|
NCBI chr18:46,324,047...46,324,933
Ensembl chr18:46,324,041...46,325,122
|
|
|
G |
CLDN4 |
claudin 4 |
increases expression |
EXP |
Mannitol results in increased expression of CLDN4 protein |
CTD |
PMID:23816505 |
|
NCBI chr 6:6,492,706...6,506,750
Ensembl chr 6:6,493,513...6,494,145
|
|
|
G |
ADRB1 |
adrenoceptor beta 1 |
multiple interactions |
EXP |
denopamine binds to and results in increased activity of ADRB1 protein |
CTD |
PMID:3831029 |
|
NCBI chr28:24,908,224...24,909,684
Ensembl chr28:24,908,224...24,909,684
|
|
|
G |
AGT |
angiotensinogen |
multiple interactions |
EXP |
Deferoxamine inhibits the reaction [AGT protein modified form results in increased susceptibility to Serotonin] |
CTD |
PMID:8021468 |
|
NCBI chr 4:8,681,192...8,694,059
Ensembl chr 4:8,683,798...8,693,880
|
|
|
G |
AVP |
arginine vasopressin |
decreases expression |
EXP |
Dexamethasone results in decreased expression of AVP protein |
CTD |
PMID:1934541 |
|
NCBI chr24:18,183,057...18,184,827
Ensembl chr24:18,183,057...18,184,883
|
|
G |
HSD11B1 |
hydroxysteroid 11-beta dehydrogenase 1 |
increases expression |
EXP |
Dexamethasone results in increased expression of HSD11B1 mRNA |
CTD |
PMID:21798686 |
|
NCBI chr 7:8,344,380...8,409,901
Ensembl chr 7:8,344,447...8,409,897
|
|
G |
NPPA |
natriuretic peptide A |
increases expression |
EXP |
Dexamethasone results in increased expression of NPPA protein |
CTD |
PMID:1934541 |
|
NCBI chr 2:84,406,317...84,408,115
Ensembl chr 2:84,396,073...84,408,385
|
|
|
G |
CYP2B6 |
cytochrome P450 2B11 |
increases metabolic processing |
EXP |
CYP2B6 protein results in increased metabolism of Dextromethorphan |
CTD |
PMID:12637241 |
|
NCBI chr 1:112,817,561...112,833,294
Ensembl chr 1:112,816,502...112,833,293
|
|
G |
CYP2D15 |
cytochrome P450 family 2 subfamily D member 15 |
affects metabolic processing |
EXP |
CYP2D15 affects the metabolism of Dextromethorphan |
CTD |
PMID:7786018 |
|
NCBI chr10:23,255,259...23,259,380
Ensembl chr10:23,255,249...23,259,298
|
|
|
G |
ACHE |
acetylcholinesterase |
decreases activity |
EXP |
Dichlorvos results in decreased activity of ACHE protein |
CTD |
PMID:89824 PMID:3627083 |
|
NCBI chr 6:8,874,747...8,879,926
Ensembl chr 6:8,873,584...8,879,702
|
|
G |
BCHE |
butyrylcholinesterase |
decreases activity |
EXP |
Dichlorvos results in decreased activity of BCHE protein |
CTD |
PMID:3627083 PMID:4631366 |
|
NCBI chr34:30,912,632...30,977,624
Ensembl chr34:30,912,632...30,977,583
|
|
|
G |
CYP2C41 |
cytochrome P450 2C41 |
affects metabolic processing increases hydroxylation |
EXP |
CYP2C9 protein affects the metabolism of Diclofenac CYP2C19 protein results in increased hydroxylation of Diclofenac |
CTD |
PMID:15677349 PMID:15801540 |
|
|
|
G |
PTGS1 |
prostaglandin-endoperoxide synthase 1 |
decreases activity |
EXP |
Diclofenac results in decreased activity of PTGS1 protein alternative form |
CTD |
PMID:12242329 |
|
NCBI chr 9:60,195,118...60,216,847
Ensembl chr 9:60,195,124...60,216,819
|
|
|
G |
CYP2E1 |
cytochrome P450 family 2 subfamily E member 1 |
multiple interactions |
EXP |
Ditiocarb inhibits the reaction [CYP2E1 protein affects the metabolism of Toluene] |
CTD |
PMID:8592870 |
|
NCBI chr28:41,079,164...41,089,188
Ensembl chr28:41,035,025...41,122,754
|
|
|
G |
ABCB1 |
ATP binding cassette subfamily B member 1 |
multiple interactions increases response to substance |
EXP |
[ML 7 results in decreased activity of MYLK protein] affects the reaction [ABCB1 protein affects the transport of Digoxin]; [Verapamil results in decreased activity of ABCB1 protein] which affects the transport of Digoxin; ABCB1 gene mutant form affects the reaction [Digoxin affects the expression of ALB mRNA]; ABCB1 gene mutant form affects the reaction [Digoxin affects the expression of DAO mRNA]; ABCB1 gene mutant form affects the reaction [Digoxin affects the expression of EBF3 mRNA]; ABCB1 gene mutant form affects the reaction [Digoxin affects the expression of GABRQ mRNA]; ABCB1 gene mutant form affects the reaction [Digoxin affects the expression of GLRA1 mRNA]; ABCB1 gene mutant form affects the reaction [Digoxin affects the expression of KLK6 mRNA]; ABCB1 gene mutant form affects the reaction [Digoxin affects the expression of MAB21L2 mRNA]; ABCB1 gene mutant form affects the reaction [Digoxin affects the expression of SLC10A4 mRNA]; ABCB1 gene mutant form affects the reaction [Digoxin affects the expression of SLC18A2 mRNA]; ABCB1 gene mutant form affects the reaction [Digoxin affects the expression of TTR mRNA]; MYL9 protein modified form affects the reaction [ABCB1 protein affects the transport of Digoxin analog] ABCB1 gene mutant form results in increased susceptibility to Digoxin; ABCB1 mutant form results in increased susceptibility to Digoxin |
CTD |
PMID:16594604 PMID:20510202 PMID:23186803 PMID:25419811 |
|
NCBI chr14:13,644,891...13,852,829
Ensembl chr14:13,542,647...13,742,727
|
|
G |
ALB |
albumin |
multiple interactions |
EXP |
ABCB1 gene mutant form affects the reaction [Digoxin affects the expression of ALB mRNA] |
CTD |
PMID:25419811 |
|
NCBI chr13:62,133,747...62,169,349
Ensembl chr13:62,053,814...62,294,709
|
|
G |
DAO |
D-amino acid oxidase |
multiple interactions |
EXP |
ABCB1 gene mutant form affects the reaction [Digoxin affects the expression of DAO mRNA] |
CTD |
PMID:25419811 |
|
NCBI chr26:18,032,663...18,057,277
Ensembl chr26:18,033,392...18,057,238
|
|
G |
EBF3 |
EBF transcription factor 3 |
multiple interactions |
EXP |
ABCB1 gene mutant form affects the reaction [Digoxin affects the expression of EBF3 mRNA] |
CTD |
PMID:25419811 |
|
NCBI chr28:38,489,635...38,601,800
Ensembl chr28:38,491,047...38,602,022
|
|
G |
GABRQ |
gamma-aminobutyric acid type A receptor subunit theta |
multiple interactions |
EXP |
ABCB1 gene mutant form affects the reaction [Digoxin affects the expression of GABRQ mRNA] |
CTD |
PMID:25419811 |
|
NCBI chr X:120,607,815...120,630,251
Ensembl chr X:120,607,686...120,628,343
|
|
G |
GLRA1 |
glycine receptor alpha 1 |
multiple interactions |
EXP |
ABCB1 gene mutant form affects the reaction [Digoxin affects the expression of GLRA1 mRNA] |
CTD |
PMID:25419811 |
|
NCBI chr 4:57,443,094...57,541,494
Ensembl chr 4:57,443,999...57,528,376
|
|
G |
INS |
insulin |
multiple interactions |
EXP |
[INS protein co-treated with Glucose] results in increased susceptibility to Digoxin; [INS protein co-treated with Glucose] results in increased uptake of Digoxin |
CTD |
PMID:140932 PMID:1013176 |
|
NCBI chr18:46,324,047...46,324,933
Ensembl chr18:46,324,041...46,325,122
|
|
G |
KLK6 |
kallikrein related peptidase 6 |
multiple interactions |
EXP |
ABCB1 gene mutant form affects the reaction [Digoxin affects the expression of KLK6 mRNA] |
CTD |
PMID:25419811 |
|
NCBI chr 1:105,902,147...105,907,585
|
|
G |
MAB21L2 |
mab-21 like 2 |
multiple interactions |
EXP |
ABCB1 gene mutant form affects the reaction [Digoxin affects the expression of MAB21L2 mRNA] |
CTD |
PMID:25419811 |
|
NCBI chr15:48,538,912...48,541,651
Ensembl chr15:48,539,955...48,541,034
|
|
G |
MYL9 |
myosin light chain 9 |
multiple interactions |
EXP |
MYL9 protein modified form affects the reaction [ABCB1 protein affects the transport of Digoxin analog] |
CTD |
PMID:20510202 |
|
NCBI chr24:25,322,800...25,329,937
Ensembl chr24:25,322,800...25,329,932
|
|
G |
MYLK |
myosin light chain kinase |
multiple interactions |
EXP |
[ML 7 results in decreased activity of MYLK protein] affects the reaction [ABCB1 protein affects the transport of Digoxin] |
CTD |
PMID:20510202 |
|
NCBI chr33:26,663,991...26,867,370
Ensembl chr33:26,664,800...26,843,181
|
|
G |
SLC10A4 |
solute carrier family 10 member 4 |
multiple interactions |
EXP |
ABCB1 gene mutant form affects the reaction [Digoxin affects the expression of SLC10A4 mRNA] |
CTD |
PMID:25419811 |
|
NCBI chr13:44,293,956...44,299,529
Ensembl chr13:44,277,094...44,299,732
|
|
G |
SLC18A2 |
solute carrier family 18 member A2 |
multiple interactions |
EXP |
ABCB1 gene mutant form affects the reaction [Digoxin affects the expression of SLC18A2 mRNA] |
CTD |
PMID:25419811 |
|
NCBI chr28:27,731,709...27,809,341
Ensembl chr28:27,731,004...27,767,993
|
|
G |
TTR |
transthyretin |
multiple interactions |
EXP |
ABCB1 gene mutant form affects the reaction [Digoxin affects the expression of TTR mRNA] |
CTD |
PMID:25419811 |
|
NCBI chr 7:57,940,354...57,947,084
Ensembl chr 7:57,914,381...57,947,058
|
|
|
G |
PLCG1 |
phospholipase C gamma 1 |
multiple interactions increases activity |
EXP |
dipalmitoylphosphatidic acid inhibits the reaction [1,2-Dipalmitoylphosphatidylcholine results in decreased activity of PLCG1 protein] dipalmitoylphosphatidic acid results in increased activity of PLCG1 protein |
CTD |
PMID:2001791 |
|
NCBI chr24:29,198,536...29,213,899
Ensembl chr24:29,198,556...29,214,714
|
|
|
G |
BCHE |
butyrylcholinesterase |
decreases activity |
EXP |
Isoflurophate results in decreased activity of BCHE protein |
CTD |
PMID:4631366 |
|
NCBI chr34:30,912,632...30,977,624
Ensembl chr34:30,912,632...30,977,583
|
|
|
G |
PLCG1 |
phospholipase C gamma 1 |
increases activity |
EXP |
dimyristoylphosphatidic acid results in increased activity of PLCG1 protein |
CTD |
PMID:2001791 |
|
NCBI chr24:29,198,536...29,213,899
Ensembl chr24:29,198,556...29,214,714
|
|
|
G |
PLCG1 |
phospholipase C gamma 1 |
increases activity |
EXP |
dioleoylphosphatidic acid results in increased activity of PLCG1 protein |
CTD |
PMID:2001791 |
|
NCBI chr24:29,198,536...29,213,899
Ensembl chr24:29,198,556...29,214,714
|
|
|
G |
CASP3 |
caspase 3 |
multiple interactions |
EXP |
Diosgenin inhibits the reaction [Calcium Oxalate results in increased activity of CASP3 protein] |
CTD |
PMID:25446497 |
|
NCBI chr16:45,920,074...45,940,507
Ensembl chr16:45,920,071...45,940,505
|
|
G |
CASP9 |
caspase 9 |
multiple interactions |
EXP |
Diosgenin inhibits the reaction [Calcium Oxalate results in increased activity of CASP9 protein] |
CTD |
PMID:25446497 |
|
NCBI chr 2:82,033,759...82,076,710
Ensembl chr 2:82,031,563...82,090,484
|
|
|
G |
CXCL8 |
C-X-C motif chemokine ligand 8 |
multiple interactions |
EXP |
Oxygen inhibits the reaction [Hydrochloric Acid results in increased expression of CXCL8 protein] |
CTD |
PMID:18339021 |
|
NCBI chr13:62,435,035...62,438,354
Ensembl chr13:62,434,422...62,438,354
|
|
G |
MMP2 |
matrix metallopeptidase 2 |
multiple interactions |
EXP |
Oxygen inhibits the reaction [Hydrochloric Acid results in increased expression of MMP2 protein] |
CTD |
PMID:18339021 |
|
NCBI chr 2:60,471,092...60,492,991
Ensembl chr 2:60,471,257...60,494,113
|
|
G |
MMP9 |
matrix metallopeptidase 9 |
multiple interactions |
EXP |
Oxygen inhibits the reaction [Hydrochloric Acid results in increased expression of MMP9 protein] |
CTD |
PMID:18339021 |
|
NCBI chr24:33,274,260...33,281,116
Ensembl chr24:33,274,268...33,281,293
|
|
|
G |
ABCB1 |
ATP binding cassette subfamily B member 1 |
increases response to substance multiple interactions |
EXP |
ABCB1 gene mutant form results in increased susceptibility to doramectin; ABCB1 mutant form results in increased susceptibility to doramectin ABCB1 gene mutant form affects the reaction [doramectin affects the expression of ALB mRNA]; ABCB1 gene mutant form affects the reaction [doramectin affects the expression of DAO mRNA]; ABCB1 gene mutant form affects the reaction [doramectin affects the expression of EBF3 mRNA]; ABCB1 gene mutant form affects the reaction [doramectin affects the expression of GABRQ mRNA]; ABCB1 gene mutant form affects the reaction [doramectin affects the expression of GLRA1 mRNA]; ABCB1 gene mutant form affects the reaction [doramectin affects the expression of KLK6 mRNA]; ABCB1 gene mutant form affects the reaction [doramectin affects the expression of MAB21L2 mRNA]; ABCB1 gene mutant form affects the reaction [doramectin affects the expression of SLC10A4 mRNA]; ABCB1 gene mutant form affects the reaction [doramectin affects the expression of SLC18A2 mRNA]; ABCB1 gene mutant form affects the reaction [doramectin affects the expression of TTR mRNA] |
CTD |
PMID:22834856 PMID:23186803 PMID:25419811 |
|
NCBI chr14:13,644,891...13,852,829
Ensembl chr14:13,542,647...13,742,727
|
|
G |
ALB |
albumin |
multiple interactions |
EXP |
ABCB1 gene mutant form affects the reaction [doramectin affects the expression of ALB mRNA] |
CTD |
PMID:25419811 |
|
NCBI chr13:62,133,747...62,169,349
Ensembl chr13:62,053,814...62,294,709
|
|
G |
DAO |
D-amino acid oxidase |
multiple interactions |
EXP |
ABCB1 gene mutant form affects the reaction [doramectin affects the expression of DAO mRNA] |
CTD |
PMID:25419811 |
|
NCBI chr26:18,032,663...18,057,277
Ensembl chr26:18,033,392...18,057,238
|
|
G |
EBF3 |
EBF transcription factor 3 |
multiple interactions |
EXP |
ABCB1 gene mutant form affects the reaction [doramectin affects the expression of EBF3 mRNA] |
CTD |
PMID:25419811 |
|
NCBI chr28:38,489,635...38,601,800
Ensembl chr28:38,491,047...38,602,022
|
|
G |
GABRQ |
gamma-aminobutyric acid type A receptor subunit theta |
multiple interactions |
EXP |
ABCB1 gene mutant form affects the reaction [doramectin affects the expression of GABRQ mRNA] |
CTD |
PMID:25419811 |
|
NCBI chr X:120,607,815...120,630,251
Ensembl chr X:120,607,686...120,628,343
|
|
G |
GLRA1 |
glycine receptor alpha 1 |
multiple interactions |
EXP |
ABCB1 gene mutant form affects the reaction [doramectin affects the expression of GLRA1 mRNA] |
CTD |
PMID:25419811 |
|
NCBI chr 4:57,443,094...57,541,494
Ensembl chr 4:57,443,999...57,528,376
|
|
G |
KLK6 |
kallikrein related peptidase 6 |
multiple interactions |
EXP |
ABCB1 gene mutant form affects the reaction [doramectin affects the expression of KLK6 mRNA] |
CTD |
PMID:25419811 |
|
NCBI chr 1:105,902,147...105,907,585
|
|
G |
MAB21L2 |
mab-21 like 2 |
multiple interactions |
EXP |
ABCB1 gene mutant form affects the reaction [doramectin affects the expression of MAB21L2 mRNA] |
CTD |
PMID:25419811 |
|
NCBI chr15:48,538,912...48,541,651
Ensembl chr15:48,539,955...48,541,034
|
|
G |
SLC10A4 |
solute carrier family 10 member 4 |
multiple interactions |
EXP |
ABCB1 gene mutant form affects the reaction [doramectin affects the expression of SLC10A4 mRNA] |
CTD |
PMID:25419811 |
|
NCBI chr13:44,293,956...44,299,529
Ensembl chr13:44,277,094...44,299,732
|
|
G |
SLC18A2 |
solute carrier family 18 member A2 |
multiple interactions |
EXP |
ABCB1 gene mutant form affects the reaction [doramectin affects the expression of SLC18A2 mRNA] |
CTD |
PMID:25419811 |
|
NCBI chr28:27,731,709...27,809,341
Ensembl chr28:27,731,004...27,767,993
|
|
G |
TTR |
transthyretin |
multiple interactions |
EXP |
ABCB1 gene mutant form affects the reaction [doramectin affects the expression of TTR mRNA] |
CTD |
PMID:25419811 |
|
NCBI chr 7:57,940,354...57,947,084
Ensembl chr 7:57,914,381...57,947,058
|
|
|
G |
ABCB1 |
ATP binding cassette subfamily B member 1 |
increases expression affects response to substance multiple interactions |
EXP |
Doxorubicin results in increased expression of ABCB1 protein ABCB1 protein affects the susceptibility to Doxorubicin valspodar inhibits the reaction [ABCB1 protein affects the susceptibility to Doxorubicin]; valspodar inhibits the reaction [ABCB1 protein results in decreased susceptibility to Doxorubicin] |
CTD |
PMID:15492788 PMID:24975508 PMID:28093773 |
|
NCBI chr14:13,644,891...13,852,829
Ensembl chr14:13,542,647...13,742,727
|
|
G |
HGF |
hepatocyte growth factor |
decreases response to substance |
EXP |
HGF protein results in decreased susceptibility to Doxorubicin |
CTD |
PMID:15688034 |
|
NCBI chr18:21,329,688...21,410,257
Ensembl chr18:21,332,817...21,410,263
|
|
G |
TNNT2 |
troponin T2, cardiac type |
affects expression |
EXP |
Doxorubicin affects the expression of TNNT2 protein |
CTD |
PMID:12322705 |
|
NCBI chr 7:1,598,306...1,620,531
Ensembl chr 7:1,598,306...1,613,741
|
|
G |
VIP |
vasoactive intestinal peptide |
decreases expression |
EXP |
Doxorubicin results in decreased expression of VIP protein |
CTD |
PMID:3711722 |
|
NCBI chr 1:42,941,655...42,950,160
Ensembl chr 1:42,941,224...42,950,700
|
|
G |
XIAP |
X-linked inhibitor of apoptosis |
affects response to substance |
EXP |
XIAP affects the susceptibility to Doxorubicin |
CTD |
PMID:16953886 |
|
NCBI chr X:95,300,234...95,356,103
Ensembl chr X:95,331,827...95,351,582
|
|
|
G |
SLCO1B2 |
solute carrier organic anion transporter family member 1B2 |
increases transport |
EXP |
SLCO1B3 protein results in increased transport of Enkephalin, D-Penicillamine (2,5)- |
CTD |
PMID:20079461 |
|
NCBI chr27:26,411,008...26,496,174
Ensembl chr27:26,411,010...26,470,989
|
|
|
G |
SELP |
selectin P |
decreases expression |
EXP |
Edaravone results in decreased expression of SELP protein |
CTD |
PMID:16041266 |
|
NCBI chr 7:28,956,428...28,997,266
Ensembl chr 7:28,958,486...28,996,313
|
|
|
G |
ABCB1 |
ATP binding cassette subfamily B member 1 |
affects response to substance |
EXP |
ABCB1 protein affects the susceptibility to emodepside |
CTD |
PMID:25660379 |
|
NCBI chr14:13,644,891...13,852,829
Ensembl chr14:13,542,647...13,742,727
|
|
|
G |
ATP2A2 |
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2 |
multiple interactions |
EXP |
[Ranolazine co-treated with Enalapril] affects the expression of ATP2A2 protein |
CTD |
PMID:18820026 |
|
NCBI chr26:8,148,181...8,209,392
Ensembl chr26:8,148,236...8,209,388
|
|
G |
EGR1 |
early growth response 1 |
multiple interactions |
EXP |
[Ranolazine co-treated with Enalapril] affects the expression of EGR1 protein |
CTD |
PMID:18820026 |
|
NCBI chr11:26,046,195...26,049,806
Ensembl chr11:26,046,228...26,048,575
|
|
G |
GATA4 |
GATA binding protein 4 |
multiple interactions |
EXP |
[Ranolazine co-treated with Enalapril] affects the expression of GATA4 protein |
CTD |
PMID:18820026 |
|
NCBI chr25:26,126,172...26,211,474
Ensembl chr25:26,127,853...26,182,989
|
|
G |
KCND3 |
potassium voltage-gated channel subfamily D member 3 |
decreases expression |
EXP |
Enalapril results in decreased expression of KCND3 mRNA |
CTD |
PMID:19732978 |
|
NCBI chr17:63,470,829...63,668,354
Ensembl chr17:63,470,415...63,668,035
|
|
G |
NAB1 |
NGFI-A binding protein 1 |
multiple interactions |
EXP |
[Ranolazine co-treated with Enalapril] affects the expression of NAB1 protein |
CTD |
PMID:18820026 |
|
NCBI chr37:1,207,619...1,243,546
Ensembl chr37:1,207,638...1,241,610
|
|
G |
NOS3 |
nitric oxide synthase 3 |
multiple interactions increases expression |
EXP |
FR 173657 inhibits the reaction [Enalapril results in increased expression of NOS3 mRNA] |
CTD |
PMID:12019275 |
|
NCBI chr16:15,054,196...15,072,454
Ensembl chr16:15,011,344...15,072,277
|
|
G |
NPPA |
natriuretic peptide A |
decreases expression multiple interactions |
EXP |
Enalapril results in decreased expression of NPPA protein FR 173657 inhibits the reaction [Enalapril results in decreased expression of NPPA protein] |
CTD |
PMID:12019275 |
|
NCBI chr 2:84,406,317...84,408,115
Ensembl chr 2:84,396,073...84,408,385
|
|
G |
REN |
renin |
increases activity multiple interactions |
EXP |
Enalapril results in increased activity of REN protein [Enalapril co-treated with FR 173657] results in increased activity of REN protein |
CTD |
PMID:12019275 |
|
NCBI chr38:744,540...766,998
Ensembl chr38:744,614...755,012
|
|
G |
SLC8A1 |
solute carrier family 8 member A1 |
multiple interactions |
EXP |
[Ranolazine co-treated with Enalapril] affects the expression of SLC8A1 protein |
CTD |
PMID:18820026 |
|
NCBI chr17:32,004,207...32,381,399
Ensembl chr17:32,005,245...32,307,700
|
|
|
G |
AR |
androgen receptor |
multiple interactions |
EXP |
Eplerenone binds to and results in decreased activity of AR protein |
CTD |
PMID:23242577 |
|
NCBI chr24:34,713,390...34,731,461 NCBI chr X:51,969,785...52,167,450
Ensembl chr X:51,969,785...52,151,912
|
|
|
G |
ALPI |
alkaline phosphatase, intestinal |
increases chemical synthesis |
EXP |
ALPI protein results in increased chemical synthesis of Estrone |
CTD |
PMID:1495895 |
|
NCBI chr25:44,107,418...44,110,947
|
|
|
G |
SLCO1B2 |
solute carrier organic anion transporter family member 1B2 |
increases transport |
EXP |
SLCO1B3 protein results in increased transport of estrone sulfate |
CTD |
PMID:20079461 |
|
NCBI chr27:26,411,008...26,496,174
Ensembl chr27:26,411,010...26,470,989
|
|
|
G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 |
decreases expression |
EXP |
Etodolac results in decreased expression of PTGS2 mRNA |
CTD |
PMID:15198222 |
|
NCBI chr 7:19,668,079...19,674,903
Ensembl chr 7:19,668,082...19,674,903
|
|
|
G |
ABCC1 |
ATP binding cassette subfamily C member 1 |
decreases response to substance |
EXP |
ABCC1 protein results in decreased susceptibility to Etoposide |
CTD |
PMID:12516967 |
|
NCBI chr 6:27,855,702...27,950,140
Ensembl chr 6:27,855,702...27,989,331
|
|
|
G |
NR1I2 |
nuclear receptor subfamily 1 group I member 2 |
increases activity |
EXP |
Felodipine results in increased activity of NR1I2 protein |
CTD |
PMID:27732639 |
|
NCBI chr33:23,444,367...23,456,405
Ensembl chr33:23,432,690...23,455,347
|
|
|
G |
CPNE6 |
copine 6 |
decreases activity |
EXP |
Flufenamic Acid results in decreased activity of DHRS4 protein |
CTD |
PMID:17827741 |
|
NCBI chr 8:4,046,532...4,058,498
Ensembl chr 8:4,046,544...4,084,744
|
|
|
G |
GNAQ |
G protein subunit alpha q |
multiple interactions |
EXP |
G(M1) Ganglioside inhibits the reaction [mastoparan results in increased activity of and affects the localization of GNAQ protein] |
CTD |
PMID:21671308 |
|
NCBI chr 1:80,733,530...80,928,065
Ensembl chr 1:80,715,366...80,928,065
|
|
G |
HEXB |
hexosaminidase subunit beta |
multiple interactions |
EXP |
G(M1) Ganglioside inhibits the reaction [mastoparan results in increased secretion of HEXB protein]; G(M1) Ganglioside inhibits the reaction [Melitten results in increased secretion of HEXB protein]; G(M1) Ganglioside inhibits the reaction [Wasp Venoms results in increased secretion of HEXB protein] |
CTD |
PMID:21334356 PMID:21671308 |
|
NCBI chr 2:57,221,809...57,248,432
Ensembl chr 2:57,222,186...57,248,417
|
|
|
G |
CFTR |
CF transmembrane conductance regulator |
decreases activity |
EXP |
Genistein results in decreased activity of CFTR protein |
CTD |
PMID:15496164 |
|
NCBI chr14:56,290,417...56,452,919
Ensembl chr14:56,290,275...56,453,977
|
|
G |
CPNE6 |
copine 6 |
decreases activity |
EXP |
Genistein results in decreased activity of DHRS4 protein |
CTD |
PMID:17827741 |
|
NCBI chr 8:4,046,532...4,058,498
Ensembl chr 8:4,046,544...4,084,744
|
|
|
G |
CCL2 |
C-C motif chemokine ligand 2 |
increases expression |
EXP |
Gentamicins results in increased expression of CCL2 protein |
CTD |
PMID:33290828 |
|
NCBI chr 9:39,008,187...39,009,932
|
|
G |
CLU |
clusterin |
increases expression |
EXP |
Gentamicins results in increased expression of CLU mRNA; Gentamicins results in increased expression of CLU protein |
CTD |
PMID:25034533 PMID:33290828 |
|
NCBI chr25:29,982,811...29,999,565
Ensembl chr25:29,982,811...29,999,563
|
|
G |
LCN2 |
lipocalin 2 |
increases expression |
EXP |
Gentamicins results in increased expression of LCN2 mRNA; Gentamicins results in increased expression of LCN2 protein |
CTD |
PMID:25034533 PMID:33290828 |
|
NCBI chr 9:55,328,118...55,342,535
Ensembl chr 9:55,328,133...55,332,038
|
|
G |
LOC607874 |
cystatin-C-like |
increases expression |
EXP |
Gentamicins results in increased expression of CST3 protein |
CTD |
PMID:33290828 |
|
NCBI chr23:49,562...53,618
|
|
G |
MIR15B |
microRNA mir-15b |
affects expression |
EXP |
Gentamicins affects the expression of MIR15B mRNA |
CTD |
PMID:33290828 |
|
NCBI chr34:26,460,663...26,460,722
Ensembl chr34:26,460,645...26,460,741
|
|
G |
MIR30A |
microRNA mir-30a |
increases expression |
EXP |
Gentamicins results in increased expression of MIR30A mRNA |
CTD |
PMID:33290828 |
|
NCBI chr12:33,783,894...33,783,956
Ensembl chr12:33,783,891...33,783,961
|
|
G |
SPP1 |
secreted phosphoprotein 1 |
increases expression |
EXP |
Gentamicins results in increased expression of SPP1 protein |
CTD |
PMID:33290828 |
|
NCBI chr32:11,354,070...11,362,325
Ensembl chr32:11,353,953...11,362,069
|
|
|
G |
INS |
insulin |
decreases abundance multiple interactions |
EXP |
INS protein results in decreased abundance of Glucose [INS protein co-treated with Glucose] results in decreased abundance of Potassium; [INS protein co-treated with Glucose] results in increased susceptibility to Digoxin; [INS protein co-treated with Glucose] results in increased uptake of Digoxin |
CTD |
PMID:140932 PMID:1013176 PMID:1646414 |
|
NCBI chr18:46,324,047...46,324,933
Ensembl chr18:46,324,041...46,325,122
|
|
|
G |
CLDN4 |
claudin 4 |
multiple interactions |
EXP |
Glutathione inhibits the reaction [Hydrogen Peroxide results in increased expression of CLDN4 protein]; Glutathione inhibits the reaction [Sodium Chloride results in increased expression of CLDN4 protein] |
CTD |
PMID:23816505 |
|
NCBI chr 6:6,492,706...6,506,750
Ensembl chr 6:6,493,513...6,494,145
|
|
G |
MAPK1 |
mitogen-activated protein kinase 1 |
multiple interactions |
EXP |
Glutathione inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK1 protein]; Glutathione inhibits the reaction [Sodium Chloride results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:23816505 |
|
NCBI chr26:31,013,607...31,132,998
Ensembl chr26:31,013,607...31,132,998
|
|
G |
MAPK3 |
mitogen-activated protein kinase 3 |
multiple interactions |
EXP |
Glutathione inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK3 protein]; Glutathione inhibits the reaction [Sodium Chloride results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:23816505 |
|
NCBI chr 6:18,109,184...18,115,728
Ensembl chr 6:18,109,222...18,114,425
|
|
G |
MAPK8 |
mitogen-activated protein kinase 8 |
multiple interactions |
EXP |
Glutathione inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK8 protein]; Glutathione inhibits the reaction [Sodium Chloride results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:23816505 |
|
NCBI chr28:323,361...410,367
Ensembl chr28:368,513...406,401
|
|
G |
MAPK9 |
mitogen-activated protein kinase 9 |
multiple interactions |
EXP |
Glutathione inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK9 protein]; Glutathione inhibits the reaction [Sodium Chloride results in increased phosphorylation of MAPK9 protein] |
CTD |
PMID:23816505 |
|
NCBI chr11:1,443,528...1,480,501
Ensembl chr11:1,443,547...1,478,119
|
|
|
G |
CFTR |
CF transmembrane conductance regulator |
decreases activity |
EXP |
Glyburide results in decreased activity of CFTR protein |
CTD |
PMID:15496164 |
|
NCBI chr14:56,290,417...56,452,919
Ensembl chr14:56,290,275...56,453,977
|
|
|
G |
SLC47A1 |
solute carrier family 47 member 1 |
decreases activity |
EXP |
hexaconazole results in decreased activity of SLC47A1 protein |
CTD |
PMID:36669674 |
|
NCBI chr 5:40,643,420...40,679,130
Ensembl chr 5:40,642,784...40,679,946
|
|
G |
SLC47A2 |
solute carrier family 47 member 2 |
decreases activity |
EXP |
hexaconazole results in decreased activity of SLC47A2 protein |
CTD |
PMID:36669674 |
|
NCBI chr 5:40,491,306...40,515,430
Ensembl chr 5:40,491,933...40,540,136
|
|
|
G |
CPNE6 |
copine 6 |
increases reduction |
EXP |
DHRS4 protein results in increased reduction of 2,3-hexanedione |
CTD |
PMID:17827741 |
|
NCBI chr 8:4,046,532...4,058,498
Ensembl chr 8:4,046,544...4,084,744
|
|
|
G |
CLDN4 |
claudin 4 |
multiple interactions increases expression |
EXP |
Acetylcysteine inhibits the reaction [Hydrogen Peroxide results in increased expression of CLDN4 protein]; Glutathione inhibits the reaction [Hydrogen Peroxide results in increased expression of CLDN4 protein]; pyrazolanthrone inhibits the reaction [Hydrogen Peroxide results in increased expression of CLDN4 protein]; U 0126 inhibits the reaction [Hydrogen Peroxide results in increased expression of CLDN4 protein] |
CTD |
PMID:23816505 |
|
NCBI chr 6:6,492,706...6,506,750
Ensembl chr 6:6,493,513...6,494,145
|
|
G |
MAPK1 |
mitogen-activated protein kinase 1 |
multiple interactions increases phosphorylation |
EXP |
Acetylcysteine inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK1 protein]; Glutathione inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:23816505 |
|
NCBI chr26:31,013,607...31,132,998
Ensembl chr26:31,013,607...31,132,998
|
|
G |
MAPK3 |
mitogen-activated protein kinase 3 |
increases phosphorylation multiple interactions |
EXP |
Hydrogen Peroxide results in increased phosphorylation of MAPK3 protein Acetylcysteine inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK3 protein]; Glutathione inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:23816505 |
|
NCBI chr 6:18,109,184...18,115,728
Ensembl chr 6:18,109,222...18,114,425
|
|
G |
MAPK8 |
mitogen-activated protein kinase 8 |
increases phosphorylation multiple interactions |
EXP |
Hydrogen Peroxide results in increased phosphorylation of MAPK8 protein Acetylcysteine inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK8 protein]; Glutathione inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:23816505 |
|
NCBI chr28:323,361...410,367
Ensembl chr28:368,513...406,401
|
|
G |
MAPK9 |
mitogen-activated protein kinase 9 |
multiple interactions increases phosphorylation |
EXP |
Acetylcysteine inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK9 protein]; Glutathione inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK9 protein]; pyrazolanthrone inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK9 protein] |
CTD |
PMID:23816505 |
|
NCBI chr11:1,443,528...1,480,501
Ensembl chr11:1,443,547...1,478,119
|
|
G |
SOD2 |
superoxide dismutase 2 |
multiple interactions decreases activity |
EXP |
Dihydrotestosterone promotes the reaction [Hydrogen Peroxide results in decreased activity of SOD2 protein] |
CTD |
PMID:16682413 |
|
NCBI chr 1:48,943,472...48,955,158
Ensembl chr 1:48,836,262...48,955,706
|
|
|
G |
SCT |
secretin |
increases abundance multiple interactions |
EXP |
SCT protein results in increased abundance of Bicarbonates [Ceruletide co-treated with SCT protein] results in increased abundance of Bicarbonates; Atropine inhibits the reaction [SCT protein results in increased abundance of Bicarbonates] |
CTD |
PMID:3562434 |
|
|
|
|
G |
PTGS1 |
prostaglandin-endoperoxide synthase 1 |
decreases activity |
EXP |
Ibuprofen results in decreased activity of PTGS1 protein alternative form |
CTD |
PMID:12242329 |
|
NCBI chr 9:60,195,118...60,216,847
Ensembl chr 9:60,195,124...60,216,819
|
|
G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 |
increases expression |
EXP |
Ibuprofen results in increased expression of PTGS2 protein |
CTD |
PMID:16105799 |
|
NCBI chr 7:19,668,079...19,674,903
Ensembl chr 7:19,668,082...19,674,903
|
|
|
G |
NOS3 |
nitric oxide synthase 3 |
increases activity |
EXP |
icariin results in increased activity of NOS3 protein |
CTD |
PMID:17438405 |
|
NCBI chr16:15,054,196...15,072,454
Ensembl chr16:15,011,344...15,072,277
|
|
|
G |
NISCH |
nischarin |
multiple interactions |
EXP |
Idazoxan binds to and results in decreased activity of NISCH protein |
CTD |
PMID:8732285 |
|
NCBI chr20:37,278,660...37,312,549
Ensembl chr20:37,279,282...37,312,636
|
|
|
G |
HEXB |
hexosaminidase subunit beta |
multiple interactions |
EXP |
Indomethacin promotes the reaction [mastoparan results in increased secretion of HEXB protein] |
CTD |
PMID:21671308 |
|
NCBI chr 2:57,221,809...57,248,432
Ensembl chr 2:57,222,186...57,248,417
|
|
G |
PTGS1 |
prostaglandin-endoperoxide synthase 1 |
decreases activity |
EXP |
Indomethacin results in decreased activity of PTGS1 protein alternative form |
CTD |
PMID:12242329 |
|
NCBI chr 9:60,195,118...60,216,847
Ensembl chr 9:60,195,124...60,216,819
|
|
|
G |
SLC22A6 |
solute carrier family 22 member 6 |
multiple interactions |
EXP |
[Lansoprazole results in decreased activity of SLC22A6 protein] which results in decreased uptake of Indican; [Omeprazole results in decreased activity of SLC22A6 protein] which results in decreased uptake of Indican; [Pantoprazole results in decreased activity of SLC22A6 protein] which results in decreased uptake of Indican |
CTD |
PMID:36243147 |
|
NCBI chr18:53,736,669...53,745,001
Ensembl chr18:53,736,959...53,744,396
|
|
|
G |
CDIPT |
CDP-diacylglycerol--inositol 3-phosphatidyltransferase |
multiple interactions |
EXP |
[Inositol promotes the reaction [CDIPT protein results in increased metabolism of Cytidine Diphosphate Diglycerides]] which results in increased abundance of Cytidine Monophosphate; Inositol promotes the reaction [CDIPT protein results in increased metabolism of Cytidine Diphosphate Diglycerides] |
CTD |
PMID:2579070 |
|
NCBI chr 6:17,910,141...17,914,573
Ensembl chr 6:17,910,192...17,914,653
|
|
|
G |
AHR |
aryl hydrocarbon receptor |
multiple interactions |
EXP |
[iprodione binds to and results in increased activity of AHR protein] which results in increased activity of CYP1A1 protein |
CTD |
PMID:24389113 |
|
NCBI chr14:31,743,704...31,793,484
Ensembl chr14:31,686,170...31,791,444
|
|
G |
CYP1A1 |
cytochrome P450 family 1 subfamily A member 1 |
multiple interactions |
EXP |
[iprodione binds to and results in increased activity of AHR protein] which results in increased activity of CYP1A1 protein |
CTD |
PMID:24389113 |
|
NCBI chr30:37,793,277...37,799,535
Ensembl chr30:37,793,508...37,796,866
|
|
|
G |
REN |
renin |
multiple interactions increases activity |
EXP |
Atenolol inhibits the reaction [Isoproterenol results in increased activity of REN protein]; Pindolol inhibits the reaction [Isoproterenol results in increased activity of REN protein]; Propranolol inhibits the reaction [Isoproterenol results in increased activity of REN protein]; xibenolol inhibits the reaction [Isoproterenol results in increased activity of REN protein] |
CTD |
PMID:6103674 |
|
NCBI chr38:744,540...766,998
Ensembl chr38:744,614...755,012
|
|
|
G |
ABCB1 |
ATP binding cassette subfamily B member 1 |
affects abundance increases response to substance multiple interactions |
EXP |
ABCB1 protein affects the abundance of Ivermectin ABCB1 gene mutant form results in increased susceptibility to Ivermectin; ABCB1 mutant form results in increased susceptibility to Ivermectin; ABCB1 protein mutant form results in increased susceptibility to Ivermectin ABCB1 gene mutant form affects the reaction [Ivermectin affects the expression of ALB mRNA]; ABCB1 gene mutant form affects the reaction [Ivermectin affects the expression of DAO mRNA]; ABCB1 gene mutant form affects the reaction [Ivermectin affects the expression of EBF3 mRNA]; ABCB1 gene mutant form affects the reaction [Ivermectin affects the expression of GABRQ mRNA]; ABCB1 gene mutant form affects the reaction [Ivermectin affects the expression of GLRA1 mRNA]; ABCB1 gene mutant form affects the reaction [Ivermectin affects the expression of KLK6 mRNA]; ABCB1 gene mutant form affects the reaction [Ivermectin affects the expression of MAB21L2 mRNA]; ABCB1 gene mutant form affects the reaction [Ivermectin affects the expression of SLC10A4 mRNA]; ABCB1 gene mutant form affects the reaction [Ivermectin affects the expression of SLC18A2 mRNA]; ABCB1 gene mutant form affects the reaction [Ivermectin affects the expression of TTR mRNA] |
CTD |
PMID:20595473 PMID:22834856 PMID:22924731 PMID:23186803 PMID:25419811 |
|
NCBI chr14:13,644,891...13,852,829
Ensembl chr14:13,542,647...13,742,727
|
|
G |
ALB |
albumin |
multiple interactions |
EXP |
ABCB1 gene mutant form affects the reaction [Ivermectin affects the expression of ALB mRNA] |
CTD |
PMID:25419811 |
|
NCBI chr13:62,133,747...62,169,349
Ensembl chr13:62,053,814...62,294,709
|
|
G |
DAO |
D-amino acid oxidase |
multiple interactions |
EXP |
ABCB1 gene mutant form affects the reaction [Ivermectin affects the expression of DAO mRNA] |
CTD |
PMID:25419811 |
|
NCBI chr26:18,032,663...18,057,277
Ensembl chr26:18,033,392...18,057,238
|
|
G |
EBF3 |
EBF transcription factor 3 |
multiple interactions |
EXP |
ABCB1 gene mutant form affects the reaction [Ivermectin affects the expression of EBF3 mRNA] |
CTD |
PMID:25419811 |
|
NCBI chr28:38,489,635...38,601,800
Ensembl chr28:38,491,047...38,602,022
|
|
G |
GABRQ |
gamma-aminobutyric acid type A receptor subunit theta |
multiple interactions |
EXP |
ABCB1 gene mutant form affects the reaction [Ivermectin affects the expression of GABRQ mRNA] |
CTD |
PMID:25419811 |
|
NCBI chr X:120,607,815...120,630,251
Ensembl chr X:120,607,686...120,628,343
|
|
G |
GLRA1 |
glycine receptor alpha 1 |
multiple interactions |
EXP |
ABCB1 gene mutant form affects the reaction [Ivermectin affects the expression of GLRA1 mRNA] |
CTD |
PMID:25419811 |
|
NCBI chr 4:57,443,094...57,541,494
Ensembl chr 4:57,443,999...57,528,376
|
|
G |
KLK6 |
kallikrein related peptidase 6 |
multiple interactions |
EXP |
ABCB1 gene mutant form affects the reaction [Ivermectin affects the expression of KLK6 mRNA] |
CTD |
PMID:25419811 |
|
NCBI chr 1:105,902,147...105,907,585
|
|
G |
MAB21L2 |
mab-21 like 2 |
multiple interactions |
EXP |
ABCB1 gene mutant form affects the reaction [Ivermectin affects the expression of MAB21L2 mRNA] |
CTD |
PMID:25419811 |
|
NCBI chr15:48,538,912...48,541,651
Ensembl chr15:48,539,955...48,541,034
|
|
G |
SLC10A4 |
solute carrier family 10 member 4 |
multiple interactions |
EXP |
ABCB1 gene mutant form affects the reaction [Ivermectin affects the expression of SLC10A4 mRNA] |
CTD |
PMID:25419811 |
|
NCBI chr13:44,293,956...44,299,529
Ensembl chr13:44,277,094...44,299,732
|
|
G |
SLC18A2 |
solute carrier family 18 member A2 |
multiple interactions |
EXP |
ABCB1 gene mutant form affects the reaction [Ivermectin affects the expression of SLC18A2 mRNA] |
CTD |
PMID:25419811 |
|
NCBI chr28:27,731,709...27,809,341
Ensembl chr28:27,731,004...27,767,993
|
|
G |
TTR |
transthyretin |
multiple interactions |
EXP |
ABCB1 gene mutant form affects the reaction [Ivermectin affects the expression of TTR mRNA] |
CTD |
PMID:25419811 |
|
NCBI chr 7:57,940,354...57,947,084
Ensembl chr 7:57,914,381...57,947,058
|
|
|
G |
ABCB1 |
ATP binding cassette subfamily B member 1 |
multiple interactions |
EXP |
kaempferol inhibits the reaction [ABCB1 protein results in increased secretion of Ritonavir] |
CTD |
PMID:15266218 |
|
NCBI chr14:13,644,891...13,852,829
Ensembl chr14:13,542,647...13,742,727
|
|
G |
CPNE6 |
copine 6 |
decreases activity |
EXP |
kaempferol results in decreased activity of DHRS4 protein |
CTD |
PMID:17827741 |
|
NCBI chr 8:4,046,532...4,058,498
Ensembl chr 8:4,046,544...4,084,744
|
|
|
G |
ABCB1 |
ATP binding cassette subfamily B member 1 |
decreases expression multiple interactions decreases activity |
EXP |
Ketoconazole results in decreased expression of ABCB1 mRNA [Ketoconazole results in decreased activity of ABCB1 protein] which results in decreased transport of Technetium Tc 99m Sestamibi |
CTD |
PMID:19754906 PMID:22620706 |
|
NCBI chr14:13,644,891...13,852,829
Ensembl chr14:13,542,647...13,742,727
|
|
G |
CYP3A12 |
cytochrome P-450 3A12 |
multiple interactions decreases activity |
EXP |
Ketoconazole inhibits the reaction [CYP3A12 protein results in increased hydroxylation of Diazepam] Ketoconazole results in decreased activity of CYP3A12 protein |
CTD |
PMID:15677349 |
|
|
|
|
G |
HSPA5 |
heat shock protein family A (Hsp70) member 5 |
increases expression |
EXP |
Dithiothreitol metabolite results in increased expression of HSPA5 protein |
CTD |
PMID:17416481 |
|
NCBI chr 9:57,850,870...57,855,607
Ensembl chr 9:57,850,922...57,855,257
|
|
|
G |
SLC22A6 |
solute carrier family 22 member 6 |
multiple interactions |
EXP |
[Lansoprazole results in decreased activity of SLC22A6 protein] which results in decreased uptake of Indican |
CTD |
PMID:36243147 |
|
NCBI chr18:53,736,669...53,745,001
Ensembl chr18:53,736,959...53,744,396
|
|
|
G |
ABCC1 |
ATP binding cassette subfamily C member 1 |
affects transport |
EXP |
ABCC1 protein affects the transport of Leukotriene C4 |
CTD |
PMID:12516967 |
|
NCBI chr 6:27,855,702...27,950,140
Ensembl chr 6:27,855,702...27,989,331
|
|
G |
ABCC2 |
ATP binding cassette subfamily C member 2 |
affects transport |
EXP |
ABCC2 protein affects the transport of Leukotriene C4 |
CTD |
PMID:15507541 |
|
NCBI chr28:12,670,885...12,740,124
Ensembl chr28:12,670,885...12,740,740
|
|
|
G |
HSD11B1 |
hydroxysteroid 11-beta dehydrogenase 1 |
increases expression |
EXP |
Lipopolysaccharides results in increased expression of HSD11B1 mRNA |
CTD |
PMID:21798686 |
|
NCBI chr 7:8,344,380...8,409,901
Ensembl chr 7:8,344,447...8,409,897
|
|
G |
HSP70 |
heat shock protein 70 |
multiple interactions |
EXP |
HSP70 protein affects the reaction [arsenite inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]]; HSP70 protein affects the reaction [arsenite inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]]; HSP70 protein affects the reaction [arsenite inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]; HSP70 protein affects the reaction [arsenite inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of RELA protein]] |
CTD |
PMID:32899721 |
|
NCBI chr12:1,285,282...1,287,670
|
|
G |
IL1B |
interleukin 1 beta |
multiple interactions increases expression |
EXP |
arsenite affects the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; HSP70 protein affects the reaction [arsenite inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]] |
CTD |
PMID:32899721 |
|
NCBI chr17:37,019,329...37,033,388
Ensembl chr17:37,019,329...37,024,458
|
|
G |
IL6 |
interleukin 6 |
multiple interactions increases expression |
EXP |
arsenite inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; HSP70 protein affects the reaction [arsenite inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]] |
CTD |
PMID:32899721 |
|
NCBI chr14:36,474,268...36,478,519
Ensembl chr14:36,473,394...36,478,519
|
|
G |
RELA |
RELA proto-oncogene, NF-kB subunit |
multiple interactions increases phosphorylation |
EXP |
arsenite inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of RELA protein]; HSP70 protein affects the reaction [arsenite inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of RELA protein]] |
CTD |
PMID:32899721 |
|
NCBI chr18:51,550,003...51,558,861
Ensembl chr18:51,550,040...51,558,875
|
|
G |
TNF |
tumor necrosis factor |
multiple interactions increases expression |
EXP |
arsenite inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; HSP70 protein affects the reaction [arsenite inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]] |
CTD |
PMID:32899721 |
|
NCBI chr12:1,074,561...1,076,425
Ensembl chr12:1,074,552...1,076,425
|
|
|
G |
CPNE6 |
copine 6 |
decreases activity |
EXP |
Lithocholic Acid results in decreased activity of DHRS4 protein |
CTD |
PMID:17827741 |
|
NCBI chr 8:4,046,532...4,058,498
Ensembl chr 8:4,046,544...4,084,744
|
|
|
G |
ABCB1 |
ATP binding cassette subfamily B member 1 |
affects response to substance increases export |
EXP |
ABCB1 protein affects the susceptibility to Loperamide ABCB1 protein results in increased export of Loperamide |
CTD |
PMID:25660379 PMID:28093773 |
|
NCBI chr14:13,644,891...13,852,829
Ensembl chr14:13,542,647...13,742,727
|
|
|
G |
CASP3 |
caspase 3 |
increases activity |
EXP |
Loratadine results in increased activity of CASP3 protein |
CTD |
PMID:20570632 |
|
NCBI chr16:45,920,074...45,940,507
Ensembl chr16:45,920,071...45,940,505
|
|
|
G |
CCL17 |
C-C motif chemokine ligand 17 |
multiple interactions |
EXP |
[Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of CCL17 mRNA]; [Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] results in increased methylation of CCL17 promoter |
CTD |
PMID:33763461 |
|
NCBI chr 2:59,001,463...59,014,347
Ensembl chr 2:59,001,464...59,005,230
|
|
G |
CCL2 |
C-C motif chemokine ligand 2 |
multiple interactions |
EXP |
[Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of CCL2 mRNA]; [Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] results in increased methylation of CCL2 promoter |
CTD |
PMID:33763461 |
|
NCBI chr 9:39,008,187...39,009,932
|
|
G |
IL13 |
interleukin 13 |
multiple interactions |
EXP |
[Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of CCL17 mRNA]; [Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of CCL2 mRNA]; [Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of IL31RA mRNA]; [Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of TSLP mRNA] |
CTD |
PMID:33763461 |
|
NCBI chr11:20,957,870...20,961,391
Ensembl chr11:20,958,464...20,961,388
|
|
G |
IL31 |
interleukin 31 |
multiple interactions |
EXP |
[Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of CCL17 mRNA]; [Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of CCL2 mRNA]; [Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of IL31RA mRNA]; [Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of TSLP mRNA] |
CTD |
PMID:33763461 |
|
NCBI chr26:7,173,151...7,175,195
Ensembl chr26:7,172,451...7,175,195
|
|
G |
IL31RA |
interleukin 31 receptor A |
multiple interactions |
EXP |
[Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of IL31RA mRNA]; [Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] results in increased methylation of IL31RA promoter |
CTD |
PMID:33763461 |
|
NCBI chr 2:43,113,194...43,198,200
Ensembl chr 2:43,144,071...43,193,293
|
|
G |
IL4 |
interleukin 4 |
multiple interactions |
EXP |
[Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of CCL17 mRNA]; [Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of CCL2 mRNA]; [Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of IL31RA mRNA]; [Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of TSLP mRNA] |
CTD |
PMID:33763461 |
|
NCBI chr11:20,972,693...20,981,539
Ensembl chr11:20,972,690...20,981,534
|
|
G |
TSLP |
thymic stromal lymphopoietin |
multiple interactions |
EXP |
[Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of TSLP mRNA]; [Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] results in increased methylation of TSLP promoter |
CTD |
PMID:33763461 |
|
NCBI chr 3:1,502,469...1,507,696
Ensembl chr 3:1,503,188...1,507,696
|
|
|
G |
PIK3CG |
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma |
multiple interactions |
EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[Norepinephrine results in increased activity of PIK3CG protein] which results in increased chemical synthesis of phosphatidylinositol 3-phosphate]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased activity of PIK3CG protein] |
CTD |
PMID:15958164 |
|
NCBI chr18:13,576,966...13,611,748
Ensembl chr18:13,570,999...13,611,141
|
|
G |
PRKCZ |
protein kinase C zeta |
multiple interactions |
EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Clonidine results in increased phosphorylation of PRKCZ protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased phosphorylation of PRKCZ protein] |
CTD |
PMID:15958164 |
|
NCBI chr 5:57,012,020...57,113,346
Ensembl chr 5:57,012,070...57,112,664
|
|
|
G |
CASP8 |
caspase 8 |
multiple interactions increases expression |
EXP |
TNFRSF1A mRNA promotes the reaction [marbofloxacin results in increased expression of CASP8 mRNA] |
CTD |
PMID:31005593 |
|
NCBI chr37:10,362,071...10,402,108
Ensembl chr37:10,391,048...10,401,822
|
|
G |
FADD |
Fas associated via death domain |
increases expression |
EXP |
marbofloxacin results in increased expression of FADD mRNA |
CTD |
PMID:31005593 |
|
NCBI chr18:48,087,447...48,094,497
|
|
G |
TNF |
tumor necrosis factor |
increases expression |
EXP |
marbofloxacin results in increased expression of TNF mRNA; marbofloxacin results in increased expression of TNF protein |
CTD |
PMID:31005593 |
|
NCBI chr12:1,074,561...1,076,425
Ensembl chr12:1,074,552...1,076,425
|
|
G |
TNFRSF1A |
TNF receptor superfamily member 1A |
multiple interactions increases expression |
EXP |
TNFRSF1A mRNA promotes the reaction [marbofloxacin results in increased expression of CASP8 mRNA]; TNFRSF1A mRNA promotes the reaction [marbofloxacin results in increased expression of TRADD mRNA] marbofloxacin results in increased expression of TNFRSF1A mRNA; marbofloxacin results in increased expression of TNFRSF1A protein |
CTD |
PMID:31005593 |
|
NCBI chr27:38,641,837...38,654,693
Ensembl chr27:38,638,753...38,700,282
|
|
G |
TRADD |
TNFRSF1A associated via death domain |
multiple interactions increases expression |
EXP |
TNFRSF1A mRNA promotes the reaction [marbofloxacin results in increased expression of TRADD mRNA] |
CTD |
PMID:31005593 |
|
NCBI chr 5:82,200,430...82,211,430
Ensembl chr 5:82,206,111...82,210,963
|
|
|
G |
ABCA5 |
ATP binding cassette subfamily A member 5 |
increases expression |
EXP |
masitinib results in increased expression of ABCA5 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 9:15,708,070...15,781,100
Ensembl chr 9:15,420,835...15,783,045
|
|
G |
ABHD14A |
abhydrolase domain containing 14A |
increases expression |
EXP |
masitinib results in increased expression of ABHD14A mRNA |
CTD |
PMID:22747577 |
|
NCBI chr20:37,738,500...37,744,689
|
|
G |
ABITRAM |
actin binding transcription modulator |
decreases expression |
EXP |
masitinib results in decreased expression of ABITRAM mRNA |
CTD |
PMID:22747577 |
|
NCBI chr11:64,094,653...64,100,078
Ensembl chr11:64,094,721...64,109,421
|
|
G |
ABLIM1 |
actin binding LIM protein 1 |
increases expression |
EXP |
masitinib results in increased expression of ABLIM1 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr28:25,260,323...25,543,369
Ensembl chr28:25,260,873...25,545,304
|
|
G |
ACAT2 |
acetyl-CoA acetyltransferase 2 |
decreases expression |
EXP |
masitinib results in decreased expression of ACAT2 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 1:49,011,665...49,029,368
Ensembl chr 1:49,011,706...49,029,327
|
|
G |
ACSM3 |
acyl-CoA synthetase medium chain family member 3 |
increases expression |
EXP |
masitinib results in increased expression of ACSM3 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 6:24,558,010...24,594,326
Ensembl chr 6:24,558,142...24,582,728
|
|
G |
ACTL7A |
actin like 7A |
increases expression |
EXP |
masitinib results in increased expression of ACTL7A mRNA |
CTD |
PMID:22747577 |
|
NCBI chr11:64,031,305...64,033,908
Ensembl chr11:64,032,358...64,033,788
|
|
G |
ACTR2 |
actin related protein 2 |
decreases expression |
EXP |
masitinib results in decreased expression of ACTR2 protein |
CTD |
PMID:22747577 |
|
NCBI chr10:64,696,068...64,733,027
Ensembl chr10:64,696,111...64,730,553
|
|
G |
ADPRH |
ADP-ribosylarginine hydrolase |
increases expression |
EXP |
masitinib results in increased expression of ADPRH mRNA |
CTD |
PMID:22747577 |
|
NCBI chr33:23,218,633...23,226,844
Ensembl chr33:23,218,101...23,224,667
|
|
G |
AGA |
aspartylglucosaminidase |
increases expression |
EXP |
masitinib results in increased expression of AGA mRNA |
CTD |
PMID:22747577 |
|
NCBI chr16:52,314,860...52,324,879
Ensembl chr16:52,314,535...52,324,894
|
|
G |
AGO2 |
argonaute RISC catalytic component 2 |
decreases expression |
EXP |
masitinib results in decreased expression of AGO2 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr13:35,169,243...35,230,252
Ensembl chr13:35,180,912...35,268,577
|
|
G |
AGRN |
agrin |
increases expression |
EXP |
masitinib results in increased expression of AGRN mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 5:56,239,621...56,273,679
Ensembl chr 5:56,239,701...56,272,745
|
|
G |
AIG1 |
androgen induced 1 |
increases expression |
EXP |
masitinib results in increased expression of AIG1 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 1:34,643,994...34,884,445
Ensembl chr 1:34,643,764...34,884,119
|
|
G |
ALAS2 |
5'-aminolevulinate synthase 2 |
increases expression |
EXP |
masitinib results in increased expression of ALAS2 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr X:46,703,477...46,731,767
Ensembl chr X:46,703,477...46,723,529
|
|
G |
ALDH5A1 |
aldehyde dehydrogenase 5 family member A1 |
decreases expression |
EXP |
masitinib results in decreased expression of ALDH5A1 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr35:22,560,005...22,590,996
Ensembl chr35:22,560,008...22,587,875
|
|
G |
AMN1 |
antagonist of mitotic exit network 1 homolog |
increases expression |
EXP |
masitinib results in increased expression of AMN1 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr27:17,044,301...17,100,444
Ensembl chr27:17,044,309...17,361,570
|
|
G |
ANKRD26 |
ankyrin repeat domain containing 26 |
increases expression |
EXP |
masitinib results in increased expression of ANKRD26 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 2:6,230,466...6,402,360
|
|
G |
ANP32E |
acidic nuclear phosphoprotein 32 family member E |
decreases expression |
EXP |
masitinib results in decreased expression of ANP32E mRNA |
CTD |
PMID:22747577 |
|
NCBI chr17:59,460,864...59,482,467
Ensembl chr17:59,462,766...59,477,936
|
|
G |
ANXA1 |
annexin A1 |
increases expression |
EXP |
masitinib results in increased expression of ANXA1 protein |
CTD |
PMID:22747577 |
|
NCBI chr 1:84,744,159...84,763,011
Ensembl chr 1:84,744,163...84,763,011
|
|
G |
ANXA6 |
annexin A6 |
increases expression |
EXP |
masitinib results in increased expression of ANXA6 protein |
CTD |
PMID:22747577 |
|
NCBI chr 4:58,091,186...58,140,102
Ensembl chr 4:58,091,251...58,139,372
|
|
G |
ARMC12 |
armadillo repeat containing 12 |
increases expression |
EXP |
masitinib results in increased expression of ARMC12 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr12:4,868,831...4,879,801
Ensembl chr12:4,869,774...4,879,793
|
|
G |
ASCC1 |
activating signal cointegrator 1 complex subunit 1 |
decreases expression |
EXP |
masitinib results in decreased expression of ASCC1 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 4:22,779,644...22,876,434
Ensembl chr 4:22,779,781...22,874,215
|
|
G |
B4GALT7 |
beta-1,4-galactosyltransferase 7 |
increases expression |
EXP |
masitinib results in increased expression of B4GALT7 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr11:3,497,860...3,507,513
Ensembl chr11:3,498,153...3,505,034
|
|
G |
BIRC5 |
baculoviral IAP repeat containing 5 |
decreases expression |
EXP |
masitinib results in decreased expression of BIRC5 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 9:2,930,308...2,959,307
|
|
G |
BTBD3 |
BTB domain containing 3 |
decreases expression |
EXP |
masitinib results in decreased expression of BTBD3 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr24:10,478,635...10,512,773
Ensembl chr24:10,479,900...10,512,185
|
|
G |
CA2 |
carbonic anhydrase 2 |
decreases expression |
EXP |
masitinib results in decreased expression of CA2 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr29:31,959,225...31,975,309
Ensembl chr29:31,935,172...31,980,579
|
|
G |
CAMK2G |
calcium/calmodulin dependent protein kinase II gamma |
increases expression |
EXP |
masitinib results in increased expression of CAMK2G mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 4:24,244,063...24,299,362
Ensembl chr 4:24,245,960...24,299,357
|
|
G |
CAPG |
capping actin protein, gelsolin like |
increases expression |
EXP |
masitinib results in increased expression of CAPG protein |
CTD |
PMID:22747577 |
|
NCBI chr17:39,619,429...39,640,944
Ensembl chr17:39,619,248...39,640,942
|
|
G |
CCT2 |
chaperonin containing TCP1 subunit 2 |
decreases expression |
EXP |
masitinib results in decreased expression of CCT2 protein |
CTD |
PMID:22747577 |
|
NCBI chr10:11,560,287...11,586,559
Ensembl chr10:11,560,396...11,578,433
|
|
G |
CD5L |
CD5 molecule like |
increases expression |
EXP |
masitinib results in increased expression of CD5L mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 7:40,516,190...40,526,528
Ensembl chr 7:40,516,190...40,526,528
|
|
G |
CDADC1 |
cytidine and dCMP deaminase domain containing 1 |
increases expression |
EXP |
masitinib results in increased expression of CDADC1 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr22:2,443,459...2,489,147
Ensembl chr22:2,436,206...2,489,016
|
|
G |
CDKN1A |
cyclin dependent kinase inhibitor 1A |
increases expression |
EXP |
masitinib results in increased expression of CDKN1A mRNA |
CTD |
PMID:22747577 |
|
NCBI chr12:5,746,898...5,755,103
Ensembl chr12:5,745,852...5,892,281
|
|
G |
CIAPIN1 |
cytokine induced apoptosis inhibitor 1 |
decreases expression |
EXP |
masitinib results in decreased expression of CIAPIN1 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 2:58,977,592...58,992,785
Ensembl chr 2:58,977,676...58,992,581
|
|
G |
CIRBP |
cold inducible RNA binding protein |
increases expression |
EXP |
masitinib results in increased expression of CIRBP mRNA |
CTD |
PMID:22747577 |
|
NCBI chr20:57,521,609...57,526,526
Ensembl chr20:57,519,119...57,526,435
|
|
G |
CLEC2B |
C-type lectin domain family 2 member B |
decreases expression |
EXP |
masitinib results in decreased expression of CLEC2B mRNA |
CTD |
PMID:22747577 |
|
NCBI chr27:36,088,754...36,143,581
Ensembl chr27:36,120,134...36,143,040
|
|
G |
CMTM7 |
CKLF like MARVEL transmembrane domain containing 7 |
increases expression |
EXP |
masitinib results in increased expression of CMTM7 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr23:12,317,636...12,382,836
Ensembl chr23:12,328,303...12,382,837
|
|
G |
CORO1A |
coronin 1A |
increases expression |
EXP |
masitinib results in increased expression of CORO1A protein |
CTD |
PMID:22747577 |
|
NCBI chr 6:18,161,850...18,167,915
Ensembl chr 6:18,160,601...18,167,818
|
|
G |
CPNE1 |
copine 1 |
increases expression |
EXP |
masitinib results in increased expression of CPNE1 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr24:24,554,636...24,589,748
Ensembl chr24:24,554,636...24,589,731
|
|
G |
CPNE6 |
copine 6 |
increases expression |
EXP |
masitinib results in increased expression of DHRS4 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 8:4,046,532...4,058,498
Ensembl chr 8:4,046,544...4,084,744
|
|
G |
CTSK |
cathepsin K |
increases expression |
EXP |
masitinib results in increased expression of CTSK mRNA |
CTD |
PMID:22747577 |
|
NCBI chr17:59,928,725...59,938,293
Ensembl chr17:59,929,287...59,938,507
|
|
G |
DLA-12 |
MHC class I DLA-12 |
increases expression |
EXP |
masitinib results in increased expression of DLA-12 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr12:933,321...936,671
Ensembl chr12:932,613...987,561
|
|
G |
DLA-64 |
MHC class I DLA-64 |
increases expression |
EXP |
masitinib results in increased expression of DLA-64 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr12:983,573...986,969
|
|
G |
DLGAP1 |
DLG associated protein 1 |
decreases expression |
EXP |
masitinib results in decreased expression of DLGAP1 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 7:70,082,563...70,949,116
Ensembl chr 7:70,081,885...70,406,213
|
|
G |
DLGAP5 |
DLG associated protein 5 |
decreases expression |
EXP |
masitinib results in decreased expression of DLGAP5 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 8:30,998,806...31,038,614
Ensembl chr 8:30,994,402...31,036,540
|
|
G |
DPCD |
deleted in primary ciliary dyskinesia homolog |
decreases expression |
EXP |
masitinib results in decreased expression of DPCD mRNA |
CTD |
PMID:22747577 |
|
NCBI chr28:14,201,302...14,219,121
Ensembl chr28:14,201,351...14,219,121
|
|
G |
DPYSL3 |
dihydropyrimidinase like 3 |
decreases expression |
EXP |
masitinib results in decreased expression of DPYSL3 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 2:41,687,725...41,809,402
Ensembl chr 2:41,690,845...41,802,376
|
|
G |
EBPL |
EBP like |
increases expression |
EXP |
masitinib results in increased expression of EBPL mRNA |
CTD |
PMID:22747577 |
|
NCBI chr22:2,116,588...2,137,935
Ensembl chr22:2,116,131...2,182,633
|
|
G |
EDEM2 |
ER degradation enhancing alpha-mannosidase like protein 2 |
increases expression |
EXP |
masitinib results in increased expression of EDEM2 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr24:24,137,228...24,165,995
Ensembl chr24:24,137,228...24,165,968
|
|
G |
EIF3A |
eukaryotic translation initiation factor 3 subunit A |
decreases expression |
EXP |
masitinib results in decreased expression of EIF3A protein |
CTD |
PMID:22747577 |
|
NCBI chr28:29,290,668...29,326,851
Ensembl chr28:29,291,422...29,326,701
|
|
G |
EIF4A1 |
eukaryotic translation initiation factor 4A1 |
decreases expression |
EXP |
masitinib results in decreased expression of EIF4A1 protein |
CTD |
PMID:22747577 |
|
NCBI chr 5:32,495,606...32,500,805
Ensembl chr 5:32,484,572...32,500,805
|
|
G |
EIF5A2 |
eukaryotic translation initiation factor 5A2 |
decreases expression |
EXP |
masitinib results in decreased expression of EIF5A2 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr34:35,309,812...35,322,382
Ensembl chr34:35,314,172...35,322,392
|
|
G |
ELSPBP1 |
epididymal sperm binding protein 1 |
increases expression |
EXP |
masitinib results in increased expression of ELSPBP1 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 1:108,159,609...108,187,224
Ensembl chr 1:108,159,611...108,188,076
|
|
G |
ETFDH |
electron transfer flavoprotein dehydrogenase |
decreases expression |
EXP |
masitinib results in decreased expression of ETFDH mRNA |
CTD |
PMID:22747577 |
|
NCBI chr15:55,752,170...55,781,118
Ensembl chr15:55,752,200...55,792,105
|
|
G |
GGT1 |
gamma-glutamyltransferase 1 |
increases expression |
EXP |
masitinib results in increased expression of GGT1 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr26:28,301,455...28,315,029
|
|
G |
GKN1 |
gastrokine 1 |
increases expression |
EXP |
masitinib results in increased expression of GKN1 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr10:67,788,329...67,793,445
Ensembl chr10:67,788,110...67,793,589
|
|
G |
GMFB |
glia maturation factor beta |
decreases expression |
EXP |
masitinib results in decreased expression of GMFB mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 8:30,394,020...30,408,408
Ensembl chr 8:30,359,499...30,408,357
|
|
G |
GSTA4 |
glutathione S-transferase alpha 4 |
increases expression |
EXP |
masitinib results in increased expression of GSTA4 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr12:20,426,724...20,443,200
Ensembl chr12:20,426,726...20,443,200
|
|
G |
GXYLT1 |
glucoside xylosyltransferase 1 |
decreases expression |
EXP |
masitinib results in decreased expression of GXYLT1 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr27:11,754,609...11,810,245
Ensembl chr27:11,765,072...11,807,787
|
|
G |
HEBP2 |
heme binding protein 2 |
decreases expression |
EXP |
masitinib results in decreased expression of HEBP2 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 1:30,716,395...30,724,814
Ensembl chr 1:30,716,606...30,724,613
|
|
G |
HERPUD1 |
homocysteine inducible ER protein with ubiquitin like domain 1 |
increases expression |
EXP |
masitinib results in increased expression of HERPUD1 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 2:59,388,492...59,400,028
Ensembl chr 2:59,388,494...59,400,003
|
|
G |
HSP90B1 |
heat shock protein 90 beta family member 1 |
increases expression |
EXP |
masitinib results in increased expression of HSP90B1 protein |
CTD |
PMID:22747577 |
|
NCBI chr15:42,456,793...42,474,122
Ensembl chr15:42,456,764...42,579,311
|
|
G |
HTR2B |
5-hydroxytryptamine receptor 2B |
increases expression |
EXP |
masitinib results in increased expression of HTR2B mRNA |
CTD |
PMID:22747577 |
|
NCBI chr25:43,042,306...43,056,361
Ensembl chr25:43,042,173...43,056,612
|
|
G |
HYAL3 |
hyaluronidase 3 |
increases expression |
EXP |
masitinib results in increased expression of HYAL3 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr20:39,041,940...39,047,388
Ensembl chr20:39,042,070...39,047,365
|
|
G |
IGFBP7 |
insulin like growth factor binding protein 7 |
increases expression |
EXP |
masitinib results in increased expression of IGFBP7 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr13:49,138,406...49,207,235
Ensembl chr13:49,138,402...49,207,394
|
|
G |
IL13 |
interleukin 13 |
increases expression |
EXP |
masitinib results in increased expression of IL13 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr11:20,957,870...20,961,391
Ensembl chr11:20,958,464...20,961,388
|
|
G |
IMMP2L |
inner mitochondrial membrane peptidase subunit 2 |
increases expression |
EXP |
masitinib results in increased expression of IMMP2L mRNA |
CTD |
PMID:22747577 |
|
NCBI chr14:50,487,679...51,336,906
|
|
G |
IRX6 |
iroquois homeobox 6 |
increases expression |
EXP |
masitinib results in increased expression of IRX6 protein |
CTD |
PMID:22747577 |
|
NCBI chr 2:60,630,688...60,636,285
Ensembl chr 2:60,630,447...60,636,416
|
|
G |
ITGA6 |
integrin subunit alpha 6 |
decreases expression |
EXP |
masitinib results in decreased expression of ITGA6 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr36:16,777,363...16,858,725
Ensembl chr36:16,776,863...16,855,449
|
|
G |
JAML |
junction adhesion molecule like |
decreases expression |
EXP |
masitinib results in decreased expression of JAML mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 5:15,485,378...15,513,457
Ensembl chr 5:15,476,582...15,513,075
|
|
G |
JUN |
Jun proto-oncogene, AP-1 transcription factor subunit |
increases expression |
EXP |
masitinib results in increased expression of JUN mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 5:50,966,698...50,968,939
|
|
G |
KCTD19 |
potassium channel tetramerization domain containing 19 |
increases expression |
EXP |
masitinib results in increased expression of KCTD19 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 5:82,060,946...82,093,248
Ensembl chr 5:82,061,449...82,093,246
|
|
G |
KLHL5 |
kelch like family member 5 |
increases expression |
EXP |
masitinib results in increased expression of KLHL5 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 3:73,258,925...73,347,262
Ensembl chr 3:73,262,895...73,344,879
|
|
G |
LBX2 |
ladybird homeobox 2 |
increases expression |
EXP |
masitinib results in increased expression of LBX2 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr17:48,641,630...48,643,411
Ensembl chr17:48,641,674...48,643,239
|
|
G |
LIN7C |
lin-7 homolog C, crumbs cell polarity complex component |
decreases expression |
EXP |
masitinib results in decreased expression of LIN7C mRNA |
CTD |
PMID:22747577 |
|
NCBI chr21:48,061,446...48,071,458
Ensembl chr21:48,064,929...48,071,429
|
|
G |
LOC474850 |
heat shock 70 kDa protein 1-like |
increases expression |
EXP |
masitinib results in increased expression of HSPA1L mRNA |
CTD |
PMID:22747577 |
|
NCBI chr12:1,281,164...1,285,010
Ensembl chr12:1,281,472...1,285,440
|
|
G |
LOC475707 |
GPN-loop GTPase 1 |
decreases expression |
EXP |
masitinib results in decreased expression of GPN1 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr17:21,654,516...21,678,435
Ensembl chr17:21,545,673...21,673,157
|
|
G |
LOC478000 |
phytanoyl-CoA hydroxylase-like |
increases expression |
EXP |
masitinib results in increased expression of PHYH mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 2:23,185,901...23,206,719
Ensembl chr 2:23,185,782...23,253,497
|
|
G |
LOC609402 |
hemoglobin subunit beta-like |
increases expression |
EXP |
masitinib results in increased expression of HBG1 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr21:28,187,535...28,188,991
|
|
G |
LONRF1 |
LON peptidase N-terminal domain and ring finger 1 |
increases expression |
EXP |
masitinib results in increased expression of LONRF1 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr16:36,220,324...36,256,896
Ensembl chr16:36,221,156...36,256,897
|
|
G |
LRP1 |
LDL receptor related protein 1 |
increases expression |
EXP |
masitinib results in increased expression of LRP1 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr10:1,260,256...1,341,705
Ensembl chr10:1,260,719...1,352,271
|
|
G |
LRP8 |
LDL receptor related protein 8 |
decreases expression |
EXP |
masitinib results in decreased expression of LRP8 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 5:55,604,878...55,684,666
Ensembl chr 5:55,604,878...55,699,736
|
|
G |
LYRM1 |
LYR motif containing 1 |
increases expression |
EXP |
masitinib results in increased expression of LYRM1 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 6:24,428,461...24,460,291
Ensembl chr 6:24,441,307...24,460,331
|
|
G |
MAGEF1 |
MAGE family member F1 |
decreases expression |
EXP |
masitinib results in decreased expression of MAGEF1 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr34:17,543,381...17,545,089
Ensembl chr34:17,543,906...17,544,868
|
|
G |
MOB1B |
MOB kinase activator 1B |
decreases expression |
EXP |
masitinib results in decreased expression of MOB1B mRNA |
CTD |
PMID:22747577 |
|
NCBI chr13:60,145,168...60,197,916
Ensembl chr13:60,145,366...60,195,463
|
|
G |
MPDZ |
multiple PDZ domain crumbs cell polarity complex component |
increases expression |
EXP |
masitinib results in increased expression of MPDZ mRNA |
CTD |
PMID:22747577 |
|
NCBI chr11:33,691,434...33,826,500
Ensembl chr11:33,692,296...33,826,437
|
|
G |
MYOZ1 |
myozenin 1 |
increases expression |
EXP |
masitinib results in increased expression of MYOZ1 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 4:24,158,532...24,165,416
Ensembl chr 4:24,158,720...24,165,392
|
|
G |
NAPG |
NSF attachment protein gamma |
decreases expression |
EXP |
masitinib results in decreased expression of NAPG mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 7:76,403,561...76,424,994
Ensembl chr 7:76,403,595...76,423,170
|
|
G |
NDUFS1 |
NADH:ubiquinone oxidoreductase core subunit S1 |
decreases expression |
EXP |
masitinib results in decreased expression of NDUFS1 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr37:14,680,908...14,713,838
Ensembl chr37:14,683,083...14,713,754
|
|
G |
NFKBIA |
NFKB inhibitor alpha |
increases expression |
EXP |
masitinib results in increased expression of NFKBIA mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 8:14,100,203...14,103,453
Ensembl chr 8:14,100,671...14,103,433
|
|
G |
NRAS |
NRAS proto-oncogene, GTPase |
decreases expression |
EXP |
masitinib results in decreased expression of NRAS mRNA |
CTD |
PMID:22747577 |
|
NCBI chr17:52,411,733...52,418,788
Ensembl chr17:52,411,733...52,418,788
|
|
G |
NSG1 |
neuronal vesicle trafficking associated 1 |
decreases expression |
EXP |
masitinib results in decreased expression of NSG1 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 3:69,805,646...69,831,200
Ensembl chr 3:69,805,592...69,831,194
|
|
G |
NTRK1 |
neurotrophic receptor tyrosine kinase 1 |
increases expression |
EXP |
masitinib results in increased expression of NTRK1 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 7:41,140,931...41,159,326
Ensembl chr 7:41,140,879...41,159,288
|
|
G |
OCA2 |
OCA2 melanosomal transmembrane protein |
decreases expression |
EXP |
masitinib results in decreased expression of OCA2 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 3:32,361,825...32,713,631
Ensembl chr 3:32,361,517...32,713,572
|
|
G |
OGT |
O-linked N-acetylglucosamine (GlcNAc) transferase |
increases expression |
EXP |
masitinib results in increased expression of OGT mRNA |
CTD |
PMID:22747577 |
|
NCBI chr X:55,821,227...55,857,597
Ensembl chr X:55,821,234...55,855,502
|
|
G |
OXCT1 |
3-oxoacid CoA-transferase 1 |
increases expression |
EXP |
masitinib results in increased expression of OXCT1 protein |
CTD |
PMID:22747577 |
|
NCBI chr 4:67,709,846...67,841,737
Ensembl chr 4:67,527,531...67,841,518
|
|
G |
PARP14 |
poly(ADP-ribose) polymerase family member 14 |
increases expression |
EXP |
masitinib results in increased expression of PARP14 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr33:25,763,282...25,798,284
Ensembl chr33:25,763,255...25,798,198
|
|
G |
PCM1 |
pericentriolar material 1 |
increases expression |
EXP |
masitinib results in increased expression of PCM1 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr16:41,212,733...41,291,654
Ensembl chr16:41,214,417...41,291,376
|
|
G |
PCOLCE2 |
procollagen C-endopeptidase enhancer 2 |
decreases expression |
EXP |
masitinib results in decreased expression of PCOLCE2 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr23:38,424,408...38,486,800
Ensembl chr23:38,426,216...38,487,252
|
|
G |
PDE6H |
phosphodiesterase 6H |
increases expression |
EXP |
masitinib results in increased expression of PDE6H mRNA |
CTD |
PMID:22747577 |
|
NCBI chr27:31,640,731...31,664,494
Ensembl chr27:31,640,737...31,664,401
|
|
G |
PDHA1 |
pyruvate dehydrogenase E1 subunit alpha 1 |
decreases expression |
EXP |
masitinib results in decreased expression of PDHA1 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr X:15,338,364...15,354,011
Ensembl chr X:15,338,202...15,387,458
|
|
G |
PDIA3 |
protein disulfide isomerase family A member 3 |
increases expression |
EXP |
masitinib results in increased expression of PDIA3 protein |
CTD |
PMID:22747577 |
|
NCBI chr30:10,487,926...10,513,437
Ensembl chr30:10,487,921...10,513,397
|
|
G |
PEBP4 |
phosphatidylethanolamine binding protein 4 |
increases expression |
EXP |
masitinib results in increased expression of PEBP4 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr25:34,329,160...34,574,086
Ensembl chr25:34,317,421...34,574,066
|
|
G |
PECAM1 |
platelet and endothelial cell adhesion molecule 1 |
increases expression |
EXP |
masitinib results in increased expression of PECAM1 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 9:12,166,124...12,219,553
Ensembl chr 9:12,166,775...12,219,778
|
|
G |
PHF10 |
PHD finger protein 10 |
increases expression |
EXP |
masitinib results in increased expression of PHF10 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr12:71,955,354...71,998,283
Ensembl chr12:71,787,082...71,998,243
|
|
G |
POMT1 |
protein O-mannosyltransferase 1 |
decreases expression |
EXP |
masitinib results in decreased expression of POMT1 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 9:52,615,349...52,631,538
Ensembl chr 9:52,615,655...52,630,836
|
|
G |
POR |
cytochrome p450 oxidoreductase |
increases expression |
EXP |
masitinib results in increased expression of POR mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 6:7,247,780...7,316,282
Ensembl chr 6:7,263,574...7,316,297
|
|
G |
PPA1 |
inorganic pyrophosphatase 1 |
decreases expression |
EXP |
masitinib results in decreased expression of PPA1 protein |
CTD |
PMID:22747577 |
|
NCBI chr 4:21,145,547...21,189,985
Ensembl chr 4:21,145,547...21,182,748
|
|
G |
PRPS2 |
phosphoribosyl pyrophosphate synthetase 2 |
decreases expression |
EXP |
masitinib results in decreased expression of PRPS2 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr X:9,281,686...9,326,551
Ensembl chr X:9,281,730...9,418,289
|
|
G |
PSMB9 |
proteasome 20S subunit beta 9 |
increases expression |
EXP |
masitinib results in increased expression of PSMB9 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr12:2,432,287...2,438,920
Ensembl chr12:2,432,505...2,438,069
|
|
G |
PSMD6 |
proteasome 26S subunit, non-ATPase 6 |
decreases expression |
EXP |
masitinib results in decreased expression of PSMD6 protein |
CTD |
PMID:22747577 |
|
NCBI chr20:27,206,801...27,220,059
|
|
G |
PSMD9 |
proteasome 26S subunit, non-ATPase 9 |
decreases expression |
EXP |
masitinib results in decreased expression of PSMD9 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr26:7,376,154...7,400,655
Ensembl chr26:7,377,413...7,400,573
|
|
G |
PTH |
parathyroid hormone |
increases expression |
EXP |
masitinib results in increased expression of PTH mRNA |
CTD |
PMID:22747577 |
|
NCBI chr21:36,417,062...36,419,967
Ensembl chr21:36,417,058...36,419,967
|
|
G |
PXYLP1 |
2-phosphoxylose phosphatase 1 |
decreases expression |
EXP |
masitinib results in decreased expression of ACPL2 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr23:37,145,065...37,197,808
Ensembl chr23:37,145,086...37,196,427
|
|
G |
R3HDM2 |
R3H domain containing 2 |
increases expression |
EXP |
masitinib results in increased expression of R3HDM2 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr10:1,377,664...1,504,008
Ensembl chr10:1,370,350...1,504,017
|
|
G |
RAB44 |
RAB44, member RAS oncogene family |
increases expression |
EXP |
masitinib results in increased expression of RAB44 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr12:5,769,056...5,804,963
Ensembl chr12:5,770,882...5,804,949
|
|
G |
RASGRP2 |
RAS guanyl releasing protein 2 |
increases expression |
EXP |
masitinib results in increased expression of RASGRP2 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr18:52,412,331...52,426,910
Ensembl chr18:52,412,367...52,426,916
|
|
G |
RCAN1 |
regulator of calcineurin 1 |
increases expression |
EXP |
masitinib results in increased expression of RCAN1 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr31:29,908,046...30,002,412
Ensembl chr31:29,909,388...30,002,418
|
|
G |
RGS13 |
regulator of G protein signaling 13 |
decreases expression |
EXP |
masitinib results in decreased expression of RGS13 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr38:6,291,146...6,316,662
Ensembl chr38:6,291,182...6,315,198
|
|
G |
SAR1B |
secretion associated Ras related GTPase 1B |
decreases expression |
EXP |
masitinib results in decreased expression of SAR1A mRNA |
CTD |
PMID:22747577 |
|
NCBI chr11:22,713,459...22,743,190
Ensembl chr11:22,717,942...22,743,124
|
|
G |
SCD |
stearoyl-CoA desaturase |
decreases expression |
EXP |
masitinib results in decreased expression of SCD mRNA |
CTD |
PMID:22747577 |
|
NCBI chr28:13,112,741...13,129,129
Ensembl chr28:13,113,006...13,125,801
|
|
G |
SELENBP1 |
selenium binding protein 1 |
increases expression |
EXP |
masitinib results in increased expression of SELENBP1 protein |
CTD |
PMID:22747577 |
|
NCBI chr17:60,410,727...60,418,770
Ensembl chr17:60,410,734...60,418,704
|
|
G |
SERPINE2 |
serpin family E member 2 |
increases expression |
EXP |
masitinib results in increased expression of SERPINE2 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr37:29,699,551...29,750,151
Ensembl chr37:29,700,024...29,724,228
|
|
G |
SFT2D2 |
SFT2 domain containing 2 |
decreases expression |
EXP |
masitinib results in decreased expression of SFT2D2 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 7:30,258,748...30,281,371
|
|
G |
SLA |
Src like adaptor |
increases expression |
EXP |
masitinib results in increased expression of SLA mRNA |
CTD |
PMID:22747577 |
|
NCBI chr13:29,503,304...29,590,679
Ensembl chr13:29,504,867...29,569,773
|
|
G |
SLC25A12 |
solute carrier family 25 member 12 |
decreases expression |
EXP |
masitinib results in decreased expression of SLC25A12 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr36:16,185,011...16,391,080
Ensembl chr36:16,185,649...16,483,016
|
|
G |
SMC5 |
structural maintenance of chromosomes 5 |
decreases expression |
EXP |
masitinib results in decreased expression of SMC5 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 1:87,192,988...87,285,678
Ensembl chr 1:87,194,867...87,285,606
|
|
G |
SRR |
serine racemase |
increases expression |
EXP |
masitinib results in increased expression of SRR mRNA |
CTD |
PMID:22747577 |
|
|
|
G |
STING1 |
stimulator of interferon response cGAMP interactor 1 |
increases expression |
EXP |
masitinib results in increased expression of TMEM173 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 2:34,783,947...34,792,204
Ensembl chr 2:34,784,232...34,789,072
|
|
G |
STOX1 |
storkhead box 1 |
increases expression |
EXP |
masitinib results in increased expression of STOX1 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 4:20,013,893...20,065,480
Ensembl chr 4:20,014,007...20,060,394
|
|
G |
STX16 |
syntaxin 16 |
increases expression |
EXP |
masitinib results in increased expression of STX16 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr24:43,425,719...43,451,828
Ensembl chr24:43,426,470...43,449,077
|
|
G |
STYXL1 |
serine/threonine/tyrosine interacting like 1 |
increases expression |
EXP |
masitinib results in increased expression of STYXL1 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 6:7,323,911...7,389,878
Ensembl chr 6:7,316,477...7,389,842
|
|
G |
TARDBP |
TAR DNA binding protein |
decreases expression |
EXP |
masitinib results in decreased expression of TARDBP protein |
CTD |
PMID:22747577 |
|
NCBI chr 2:84,987,752...84,998,136
Ensembl chr 2:84,989,952...84,998,593
|
|
G |
TBC1D14 |
TBC1 domain family member 14 |
decreases expression |
EXP |
masitinib results in decreased expression of TBC1D14 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 3:58,992,743...59,097,581
Ensembl chr 3:58,926,237...59,097,621
|
|
G |
TCN2 |
transcobalamin 2 |
increases expression |
EXP |
masitinib results in increased expression of TCN2 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr26:23,693,664...23,710,342
Ensembl chr26:23,693,773...23,709,832
|
|
G |
TCP1 |
t-complex 1 |
decreases expression |
EXP |
masitinib results in decreased expression of TCP1 protein |
CTD |
PMID:22747577 |
|
NCBI chr 1:49,029,260...49,038,023
Ensembl chr 1:49,029,282...49,038,020
|
|
G |
TEAD4 |
TEA domain transcription factor 4 |
increases expression |
EXP |
masitinib results in increased expression of TEAD4 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr27:41,744,100...41,783,223
Ensembl chr27:41,748,871...41,803,556
|
|
G |
THEMIS2 |
thymocyte selection associated family member 2 |
decreases expression |
EXP |
masitinib results in decreased expression of THEMIS2 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 2:72,465,719...72,501,962
Ensembl chr 2:72,464,026...72,502,928
|
|
G |
TM2D2 |
TM2 domain containing 2 |
increases expression |
EXP |
masitinib results in increased expression of TM2D2 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr16:26,551,563...26,557,554
Ensembl chr16:26,551,628...26,556,285
|
|
G |
TMEM108 |
transmembrane protein 108 |
increases expression |
EXP |
masitinib results in increased expression of TMEM108 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr23:29,992,038...30,331,791
Ensembl chr23:29,992,021...30,396,840
|
|
G |
TMEM260 |
transmembrane protein 260 |
increases expression |
EXP |
masitinib results in increased expression of TMEM260 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 8:32,238,992...32,309,320
Ensembl chr 8:32,238,988...32,306,317
|
|
G |
TNFSF10 |
TNF superfamily member 10 |
increases expression |
EXP |
masitinib results in increased expression of TNFSF10 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr34:36,719,249...36,734,989
Ensembl chr34:36,670,849...36,735,060
|
|
G |
TNPO1 |
transportin 1 |
decreases expression |
EXP |
masitinib results in decreased expression of TNPO1 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 2:55,795,737...55,859,366
Ensembl chr 2:55,799,907...55,851,213
|
|
G |
TNS1 |
tensin 1 |
decreases expression |
EXP |
masitinib results in decreased expression of TNS1 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr37:24,578,855...24,776,153
Ensembl chr37:24,581,806...24,808,049
|
|
G |
TOX |
thymocyte selection associated high mobility group box |
increases expression |
EXP |
masitinib results in increased expression of TOX mRNA |
CTD |
PMID:22747577 |
|
NCBI chr29:9,542,471...9,841,759
Ensembl chr29:9,544,561...9,842,034
|
|
G |
TSHB |
thyroid stimulating hormone subunit beta |
increases expression |
EXP |
masitinib results in increased expression of TSHB mRNA |
CTD |
PMID:22747577 |
|
NCBI chr17:52,659,137...52,685,388
Ensembl chr17:52,681,357...52,685,390
|
|
G |
TSPAN2 |
tetraspanin 2 |
increases expression |
EXP |
masitinib results in increased expression of TSPAN2 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr17:52,692,744...52,749,048
Ensembl chr17:52,694,603...52,744,276
|
|
G |
TTC38 |
tetratricopeptide repeat domain 38 |
increases expression |
EXP |
masitinib results in increased expression of TTC38 protein |
CTD |
PMID:22747577 |
|
NCBI chr10:19,887,285...19,910,347
Ensembl chr10:19,773,373...19,910,683
|
|
G |
TTLL1 |
TTL family tubulin polyglutamylase complex subunit L1 |
decreases expression |
EXP |
masitinib results in decreased expression of TTLL1 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr10:22,456,150...22,492,375
Ensembl chr10:22,456,146...22,488,505
|
|
G |
UCHL3 |
ubiquitin C-terminal hydrolase L3 |
increases expression |
EXP |
masitinib results in increased expression of UCHL3 protein |
CTD |
PMID:22747577 |
|
NCBI chr22:29,348,962...29,397,944
Ensembl chr22:29,348,706...29,407,965
|
|
G |
UQCC1 |
ubiquinol-cytochrome c reductase complex assembly factor 1 |
decreases expression |
EXP |
masitinib results in decreased expression of UQCC mRNA |
CTD |
PMID:22747577 |
|
NCBI chr24:24,285,147...24,381,819
Ensembl chr24:24,286,320...24,381,699
|
|
G |
UROD |
uroporphyrinogen decarboxylase |
increases expression |
EXP |
masitinib results in increased expression of UROD protein |
CTD |
PMID:22747577 |
|
NCBI chr15:15,313,808...15,317,130
Ensembl chr15:15,312,674...15,320,010
|
|
G |
UROS |
uroporphyrinogen III synthase |
increases expression |
EXP |
masitinib results in increased expression of UROS mRNA |
CTD |
PMID:22747577 |
|
NCBI chr28:34,952,074...34,983,532
Ensembl chr28:34,948,003...34,983,532
|
|
G |
VCPKMT |
valosin containing protein lysine methyltransferase |
decreases expression |
EXP |
masitinib results in decreased expression of VCPKMT mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 8:26,611,333...26,636,700
Ensembl chr 8:26,625,677...26,636,316
|
|
G |
WAPL |
WAPL cohesin release factor |
decreases expression |
EXP |
masitinib results in decreased expression of WAPAL mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 4:34,219,644...34,297,456
Ensembl chr 4:34,219,645...34,302,839
|
|
G |
YWHAZ |
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta |
increases expression |
EXP |
masitinib results in increased expression of YWHAZ protein |
CTD |
PMID:22747577 |
|
NCBI chr13:2,729,404...2,764,422
|
|
G |
ZNF23 |
zinc finger protein 23 |
increases expression |
EXP |
masitinib results in increased expression of ZNF23 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 5:77,246,374...77,260,761
Ensembl chr 5:77,246,667...77,260,350
|
|
|
G |
GNAQ |
G protein subunit alpha q |
multiple interactions |
EXP |
G(M1) Ganglioside inhibits the reaction [mastoparan results in increased activity of and affects the localization of GNAQ protein]; ganglioside, GD1a inhibits the reaction [mastoparan results in increased activity of and affects the localization of GNAQ protein]; mastoparan results in increased activity of and affects the localization of GNAQ protein |
CTD |
PMID:21671308 |
|
NCBI chr 1:80,733,530...80,928,065
Ensembl chr 1:80,715,366...80,928,065
|
|
G |
HEXB |
hexosaminidase subunit beta |
multiple interactions increases secretion |
EXP |
G(M1) Ganglioside inhibits the reaction [mastoparan results in increased secretion of HEXB protein]; ganglioside, GD1a inhibits the reaction [mastoparan results in increased secretion of HEXB protein]; Indomethacin promotes the reaction [mastoparan results in increased secretion of HEXB protein]; methyl-beta-cyclodextrin promotes the reaction [mastoparan results in increased secretion of HEXB protein]; Pertussis Toxin inhibits the reaction [mastoparan results in increased secretion of HEXB protein]; Quinacrine promotes the reaction [mastoparan results in increased secretion of HEXB protein]; YM-254890 inhibits the reaction [mastoparan results in increased secretion of HEXB protein] |
CTD |
PMID:21671308 |
|
NCBI chr 2:57,221,809...57,248,432
Ensembl chr 2:57,222,186...57,248,417
|
|
|
G |
HEXB |
hexosaminidase subunit beta |
multiple interactions increases secretion |
EXP |
G(M1) Ganglioside inhibits the reaction [Melitten results in increased secretion of HEXB protein]; sialogangliosides inhibits the reaction [Melitten results in increased secretion of HEXB protein]; trisialoganglioside GT1 inhibits the reaction [Melitten results in increased secretion of HEXB protein] |
CTD |
PMID:21334356 |
|
NCBI chr 2:57,221,809...57,248,432
Ensembl chr 2:57,222,186...57,248,417
|
|
|
G |
CPNE6 |
copine 6 |
increases reduction |
EXP |
DHRS4 protein results in increased reduction of Vitamin K 3 |
CTD |
PMID:17827741 |
|
NCBI chr 8:4,046,532...4,058,498
Ensembl chr 8:4,046,544...4,084,744
|
|
|
G |
PTGS1 |
prostaglandin-endoperoxide synthase 1 |
decreases activity |
EXP |
Dipyrone results in decreased activity of PTGS1 protein alternative form |
CTD |
PMID:12242329 |
|
NCBI chr 9:60,195,118...60,216,847
Ensembl chr 9:60,195,124...60,216,819
|
|
|
G |
HEXB |
hexosaminidase subunit beta |
multiple interactions |
EXP |
methyl-beta-cyclodextrin promotes the reaction [mastoparan results in increased secretion of HEXB protein] |
CTD |
PMID:21671308 |
|
NCBI chr 2:57,221,809...57,248,432
Ensembl chr 2:57,222,186...57,248,417
|
|
|
G |
ATP2A2 |
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2 |
multiple interactions |
EXP |
[Ranolazine co-treated with Metoprolol] affects the expression of ATP2A2 protein |
CTD |
PMID:18820026 |
|
NCBI chr26:8,148,181...8,209,392
Ensembl chr26:8,148,236...8,209,388
|
|
G |
CYP2D15 |
cytochrome P450 family 2 subfamily D member 15 |
affects metabolic processing |
EXP |
CYP2D15 affects the metabolism of Metoprolol |
CTD |
PMID:7786018 |
|
NCBI chr10:23,255,259...23,259,380
Ensembl chr10:23,255,249...23,259,298
|
|
G |
EGR1 |
early growth response 1 |
multiple interactions |
EXP |
[Ranolazine co-treated with Metoprolol] affects the expression of EGR1 protein |
CTD |
PMID:18820026 |
|
NCBI chr11:26,046,195...26,049,806
Ensembl chr11:26,046,228...26,048,575
|
|
G |
GATA4 |
GATA binding protein 4 |
multiple interactions |
EXP |
[Ranolazine co-treated with Metoprolol] affects the expression of GATA4 protein |
CTD |
PMID:18820026 |
|
NCBI chr25:26,126,172...26,211,474
Ensembl chr25:26,127,853...26,182,989
|
|
G |
NAB1 |
NGFI-A binding protein 1 |
multiple interactions |
EXP |
[Ranolazine co-treated with Metoprolol] affects the expression of NAB1 protein |
CTD |
PMID:18820026 |
|
NCBI chr37:1,207,619...1,243,546
Ensembl chr37:1,207,638...1,241,610
|
|
G |
SLC8A1 |
solute carrier family 8 member A1 |
multiple interactions |
EXP |
[Ranolazine co-treated with Metoprolol] affects the expression of SLC8A1 protein |
CTD |
PMID:18820026 |
|
NCBI chr17:32,004,207...32,381,399
Ensembl chr17:32,005,245...32,307,700
|
|
|
G |
ABCB1 |
ATP binding cassette subfamily B member 1 |
increases response to substance |
EXP |
ABCB1 mutant form results in increased susceptibility to Mexiletine |
CTD |
PMID:16594604 |
|
NCBI chr14:13,644,891...13,852,829
Ensembl chr14:13,542,647...13,742,727
|
|
|
G |
ABCB1 |
ATP binding cassette subfamily B member 1 |
increases response to substance multiple interactions |
EXP |
ABCB1 gene mutant form results in increased susceptibility to moxidectin; ABCB1 mutant form results in increased susceptibility to moxidectin ABCB1 gene mutant form affects the reaction [moxidectin affects the expression of ALB mRNA]; ABCB1 gene mutant form affects the reaction [moxidectin affects the expression of DAO mRNA]; ABCB1 gene mutant form affects the reaction [moxidectin affects the expression of EBF3 mRNA]; ABCB1 gene mutant form affects the reaction [moxidectin affects the expression of GABRQ mRNA]; ABCB1 gene mutant form affects the reaction [moxidectin affects the expression of GLRA1 mRNA]; ABCB1 gene mutant form affects the reaction [moxidectin affects the expression of KLK6 mRNA]; ABCB1 gene mutant form affects the reaction [moxidectin affects the expression of MAB21L2 mRNA]; ABCB1 gene mutant form affects the reaction [moxidectin affects the expression of SLC10A4 mRNA]; ABCB1 gene mutant form affects the reaction [moxidectin affects the expression of SLC18A2 mRNA]; ABCB1 gene mutant form affects the reaction [moxidectin affects the expression of TTR mRNA] |
CTD |
PMID:23186803 PMID:25419811 |
|
NCBI chr14:13,644,891...13,852,829
Ensembl chr14:13,542,647...13,742,727
|
|
G |
ALB |
albumin |
multiple interactions |
EXP |
ABCB1 gene mutant form affects the reaction [moxidectin affects the expression of ALB mRNA] |
CTD |
PMID:25419811 |
|
NCBI chr13:62,133,747...62,169,349
Ensembl chr13:62,053,814...62,294,709
|
|
G |
DAO |
D-amino acid oxidase |
multiple interactions |
EXP |
ABCB1 gene mutant form affects the reaction [moxidectin affects the expression of DAO mRNA] |
CTD |
PMID:25419811 |
|
NCBI chr26:18,032,663...18,057,277
Ensembl chr26:18,033,392...18,057,238
|
|
G |
EBF3 |
EBF transcription factor 3 |
multiple interactions |
EXP |
ABCB1 gene mutant form affects the reaction [moxidectin affects the expression of EBF3 mRNA] |
CTD |
PMID:25419811 |
|
NCBI chr28:38,489,635...38,601,800
Ensembl chr28:38,491,047...38,602,022
|
|
G |
GABRQ |
gamma-aminobutyric acid type A receptor subunit theta |
multiple interactions |
EXP |
ABCB1 gene mutant form affects the reaction [moxidectin affects the expression of GABRQ mRNA] |
CTD |
PMID:25419811 |
|
NCBI chr X:120,607,815...120,630,251
Ensembl chr X:120,607,686...120,628,343
|
|
G |
GLRA1 |
glycine receptor alpha 1 |
multiple interactions |
EXP |
ABCB1 gene mutant form affects the reaction [moxidectin affects the expression of GLRA1 mRNA] |
CTD |
PMID:25419811 |
|
NCBI chr 4:57,443,094...57,541,494
Ensembl chr 4:57,443,999...57,528,376
|
|
G |
KLK6 |
kallikrein related peptidase 6 |
multiple interactions |
EXP |
ABCB1 gene mutant form affects the reaction [moxidectin affects the expression of KLK6 mRNA] |
CTD |
PMID:25419811 |
|
NCBI chr 1:105,902,147...105,907,585
|
|
G |
MAB21L2 |
mab-21 like 2 |
multiple interactions |
EXP |
ABCB1 gene mutant form affects the reaction [moxidectin affects the expression of MAB21L2 mRNA] |
CTD |
PMID:25419811 |
|
NCBI chr15:48,538,912...48,541,651
Ensembl chr15:48,539,955...48,541,034
|
|
G |
SLC10A4 |
solute carrier family 10 member 4 |
multiple interactions |
EXP |
ABCB1 gene mutant form affects the reaction [moxidectin affects the expression of SLC10A4 mRNA] |
CTD |
PMID:25419811 |
|
NCBI chr13:44,293,956...44,299,529
Ensembl chr13:44,277,094...44,299,732
|
|
G |
SLC18A2 |
solute carrier family 18 member A2 |
multiple interactions |
EXP |
ABCB1 gene mutant form affects the reaction [moxidectin affects the expression of SLC18A2 mRNA] |
CTD |
PMID:25419811 |
|
NCBI chr28:27,731,709...27,809,341
Ensembl chr28:27,731,004...27,767,993
|
|
G |
TTR |
transthyretin |
multiple interactions |
EXP |
ABCB1 gene mutant form affects the reaction [moxidectin affects the expression of TTR mRNA] |
CTD |
PMID:25419811 |
|
NCBI chr 7:57,940,354...57,947,084
Ensembl chr 7:57,914,381...57,947,058
|
|
|
G |
ABCB1 |
ATP binding cassette subfamily B member 1 |
multiple interactions |
EXP |
[ML 7 results in decreased activity of MYLK protein] affects the reaction [ABCB1 protein affects the transport of Digoxin] |
CTD |
PMID:20510202 |
|
NCBI chr14:13,644,891...13,852,829
Ensembl chr14:13,542,647...13,742,727
|
|
G |
MYLK |
myosin light chain kinase |
multiple interactions |
EXP |
[ML 7 results in decreased activity of MYLK protein] affects the reaction [ABCB1 protein affects the transport of Digoxin] |
CTD |
PMID:20510202 |
|
NCBI chr33:26,663,991...26,867,370
Ensembl chr33:26,664,800...26,843,181
|
|
|
G |
AKAP12 |
A-kinase anchoring protein 12 |
increases expression |
EXP |
mocetinostat results in increased expression of AKAP12 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr 1:41,614,893...41,712,350
Ensembl chr 1:41,614,714...41,709,798
|
|
G |
ANK1 |
ankyrin 1 |
decreases expression |
EXP |
mocetinostat results in decreased expression of ANK1 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr16:23,858,299...23,966,181
Ensembl chr16:23,766,193...23,964,226
|
|
G |
ANK3 |
ankyrin 3 |
increases expression |
EXP |
mocetinostat results in increased expression of ANK3 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr 4:12,166,275...12,827,175
Ensembl chr 4:12,167,550...12,827,037
|
|
G |
AP2M1 |
adaptor related protein complex 2 subunit mu 1 |
decreases expression |
EXP |
mocetinostat results in decreased expression of AP2M1 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr34:17,071,199...17,080,445
Ensembl chr34:17,071,235...17,080,445
|
|
G |
AP2S1 |
adaptor related protein complex 2 subunit sigma 1 |
decreases expression |
EXP |
mocetinostat results in decreased expression of AP2S1 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr 1:109,094,098...109,105,233
Ensembl chr 1:109,082,221...109,105,230
|
|
G |
AP3S1 |
adaptor related protein complex 3 subunit sigma 1 |
increases expression |
EXP |
mocetinostat results in increased expression of AP3S1 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr11:5,543,140...5,611,322
Ensembl chr11:5,543,222...5,610,930
|
|
G |
ARF4 |
ADP ribosylation factor 4 |
increases expression |
EXP |
mocetinostat results in increased expression of ARF4 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr20:32,849,725...32,871,127
Ensembl chr20:32,849,757...32,870,721
|
|
G |
ATG4D |
autophagy related 4D cysteine peptidase |
decreases expression |
EXP |
mocetinostat results in decreased expression of ATG4D mRNA |
CTD |
PMID:27255383 |
|
NCBI chr20:50,618,458...50,623,703
Ensembl chr20:50,618,459...50,624,179
|
|
G |
ATG7 |
autophagy related 7 |
decreases expression |
EXP |
mocetinostat results in decreased expression of ATG7 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr20:6,916,354...7,154,849
Ensembl chr20:6,916,515...7,154,800
|
|
G |
ATP1A1 |
ATPase Na+/K+ transporting subunit alpha 1 |
increases expression |
EXP |
mocetinostat results in increased expression of ATP1A1 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr17:53,828,482...53,847,043
Ensembl chr17:53,813,976...53,847,167
|
|
G |
BCAP29 |
B cell receptor associated protein 29 |
increases expression |
EXP |
mocetinostat results in increased expression of BCAP29 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr18:12,969,594...13,021,948
Ensembl chr18:12,970,411...13,022,022
|
|
G |
BLOC1S1 |
biogenesis of lysosomal organelles complex 1 subunit 1 |
decreases expression |
EXP |
mocetinostat results in decreased expression of BLOC1S1 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr10:116,993...120,244
|
|
G |
BNIP1 |
BCL2 interacting protein 1 |
decreases expression |
EXP |
mocetinostat results in decreased expression of BNIP1 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr 4:39,255,685...39,303,485
Ensembl chr 4:39,289,776...39,303,430
|
|
G |
CACNB3 |
calcium voltage-gated channel auxiliary subunit beta 3 |
increases expression |
EXP |
mocetinostat results in increased expression of CACNB3 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr27:5,705,587...5,714,620
Ensembl chr27:5,706,064...5,717,647
|
|
G |
CAMK1D |
calcium/calmodulin dependent protein kinase ID |
increases expression |
EXP |
mocetinostat results in increased expression of CAMK1D mRNA |
CTD |
PMID:27255383 |
|
NCBI chr 2:23,680,395...24,113,922
Ensembl chr 2:23,685,672...24,114,084
|
|
G |
CASK |
calcium/calmodulin dependent serine protein kinase |
increases expression |
EXP |
mocetinostat results in increased expression of CASK mRNA |
CTD |
PMID:27255383 |
|
NCBI chr X:35,939,117...36,296,438
Ensembl chr X:35,940,647...36,297,014
|
|
G |
CAV1 |
caveolin 1 |
increases expression |
EXP |
mocetinostat results in increased expression of CAV1 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr14:55,458,934...55,494,563
Ensembl chr14:55,461,048...55,492,935
|
|
G |
CBY1 |
chibby 1, beta catenin antagonist |
decreases expression |
EXP |
mocetinostat results in decreased expression of CBY1 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr10:26,125,064...26,134,693
Ensembl chr10:26,125,189...26,128,285
|
|
G |
CHMP4B |
charged multivesicular body protein 4B |
decreases expression |
EXP |
mocetinostat results in decreased expression of CHMP4B mRNA |
CTD |
PMID:27255383 |
|
NCBI chr24:22,995,677...23,050,084
Ensembl chr24:22,995,672...23,049,287
|
|
G |
CHMP5 |
charged multivesicular body protein 5 |
decreases expression |
EXP |
mocetinostat results in decreased expression of CHMP5 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr11:50,363,488...50,376,081
|
|
G |
CHMP6 |
charged multivesicular body protein 6 |
decreases expression |
EXP |
mocetinostat results in decreased expression of CHMP6 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr 9:997,951...1,001,659
Ensembl chr 9:998,653...1,002,538
|
|
G |
CLTCL1 |
clathrin heavy chain like 1 |
increases expression |
EXP |
mocetinostat results in increased expression of CLTCL1 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr26:29,907,235...30,002,136
Ensembl chr26:29,906,278...30,002,128
|
|
G |
COPB1 |
COPI coat complex subunit beta 1 |
increases expression |
EXP |
mocetinostat results in increased expression of COPB1 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr21:37,186,380...37,224,549
Ensembl chr21:37,186,424...37,224,519
|
|
G |
COPB2 |
COPI coat complex subunit beta 2 |
decreases expression |
EXP |
mocetinostat results in decreased expression of COPB2 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr23:35,536,520...35,604,708
Ensembl chr23:35,536,615...35,566,569
|
|
G |
COPG1 |
COPI coat complex subunit gamma 1 |
decreases expression |
EXP |
mocetinostat results in decreased expression of COPG1 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr20:2,832,150...2,860,356
Ensembl chr20:2,832,198...2,860,320
|
|
G |
DERL2 |
derlin 2 |
decreases expression |
EXP |
mocetinostat results in decreased expression of DERL2 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr 5:31,319,660...31,330,846
Ensembl chr 5:31,319,717...31,330,841
|
|
G |
DNM1L |
dynamin 1 like |
decreases expression |
EXP |
mocetinostat results in decreased expression of DNM1L mRNA |
CTD |
PMID:27255383 |
|
NCBI chr27:16,161,855...16,211,983
Ensembl chr27:16,163,357...16,211,957
|
|
G |
GPAA1 |
glycosylphosphatidylinositol anchor attachment 1 |
decreases expression |
EXP |
mocetinostat results in decreased expression of GPAA1 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr13:37,577,162...37,580,346
Ensembl chr13:37,576,354...37,580,345
|
|
G |
HPS4 |
HPS4 biogenesis of lysosomal organelles complex 3 subunit 2 |
decreases expression |
EXP |
mocetinostat results in decreased expression of HPS4 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr26:20,131,658...20,157,532
Ensembl chr26:19,933,281...20,157,058
|
|
G |
HRC |
histidine rich calcium binding protein |
decreases expression |
EXP |
mocetinostat results in decreased expression of HRC mRNA |
CTD |
PMID:27255383 |
|
NCBI chr 1:107,304,718...107,308,741
Ensembl chr 1:107,304,924...107,308,740
|
|
G |
KCNK1 |
potassium two pore domain channel subfamily K member 1 |
increases expression |
EXP |
mocetinostat results in increased expression of KCNK1 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr 4:6,117,406...6,139,390
Ensembl chr 4:6,118,373...6,122,093
|
|
G |
KCNMB4 |
potassium calcium-activated channel subfamily M regulatory beta subunit 4 |
increases expression |
EXP |
mocetinostat results in increased expression of KCNMB4 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr10:12,211,372...12,251,739
|
|
G |
KCNS3 |
potassium voltage-gated channel modifier subfamily S member 3 |
increases expression |
EXP |
mocetinostat results in increased expression of KCNS3 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr17:13,297,242...13,338,319
Ensembl chr17:13,336,374...13,337,849
|
|
G |
KIF5A |
kinesin family member 5A |
increases expression |
EXP |
mocetinostat results in increased expression of KIF5A mRNA |
CTD |
PMID:27255383 |
|
NCBI chr10:1,637,007...1,666,790
Ensembl chr10:1,636,932...1,664,767
|
|
G |
KIF5B |
kinesin family member 5B |
decreases expression |
EXP |
mocetinostat results in decreased expression of KIF5B mRNA |
CTD |
PMID:27255383 |
|
NCBI chr 2:14,835,906...14,880,896
Ensembl chr 2:14,835,901...14,878,251
|
|
G |
KIF5C |
kinesin family member 5C |
increases expression |
EXP |
mocetinostat results in increased expression of KIF5C mRNA |
CTD |
PMID:27255383 |
|
NCBI chr19:50,535,622...50,684,485
Ensembl chr19:50,535,456...50,668,738
|
|
G |
LAMTOR1 |
late endosomal/lysosomal adaptor, MAPK and MTOR activator 1 |
decreases expression |
EXP |
mocetinostat results in decreased expression of LAMTOR1 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr21:25,981,170...25,986,942
Ensembl chr21:25,981,254...25,996,432
|
|
G |
LAMTOR2 |
late endosomal/lysosomal adaptor, MAPK and MTOR activator 2 |
decreases expression |
EXP |
mocetinostat results in decreased expression of LAMTOR2 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr 7:41,760,632...41,764,926
Ensembl chr 7:41,760,638...41,763,299
|
|
G |
LOC478702 |
tubulin beta-2B chain |
increases expression |
EXP |
mocetinostat results in increased expression of TUBB2B mRNA |
|